

Objection Deadline: December 18, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**FOURTEENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD OF OCTOBER 1, 2020 THROUGH OCTOBER 31, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	October 1, 2020	October 31, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$674,842.40 (80% of \$843,553.00)	
Total expenses requested in this statement:	\$4.89	
Total fees and expenses requested in this statement:	\$674,847.29	
This is a(n): X Monthly Application Interim Application Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD OCTOBER 1, 2020 THROUGH OCTOBER 31, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	12.3	\$ 14,698.50
Richard Collura	Managing Director	\$1,090	19.8	21,582.00
Jesse DelConte	Director	\$950	173.8	165,110.00
Kevin M McCafferty	Director	\$950	184.9	175,655.00
Gabe J Koch	Director	\$840	155.1	130,284.00
HS Bhattal	Director	\$840	44.8	37,632.00
Sam J Canniff	Senior Vice President	\$645	7.7	4,966.50
Kristina Galbraith	Senior Vice President	\$645	2.5	1,612.50
Kaitlyn A Sundt	Senior Vice President	\$510	2.4	1,224.00
Andrew D DePalma	Vice President	\$515	161.6	83,224.00
Lan T Nguyen	Vice President	\$515	89.4	46,041.00
Sam K Lemack	Vice President	\$515	165.6	85,284.00
Nate A Simon	Vice President	\$515	126.6	65,199.00
Tammy Brewer	Vice President	\$450	1.6	720.00
Melanie McCabe	Vice President	\$415	22.7	9,420.50
Edward Duhalde	Vice President	\$360	2.5	900.00
Total Professional Hours and Fees			1,173.3	\$ 843,553.00
Less 50% Travel Fees				-
Subtotal				\$ 843,553.00
Less 20% Holdback				(168,710.60)
Invoice Total				\$ 674,842.40
Average Billing Rate				\$ 718.96

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD OCTOBER 1, 2020 THROUGH OCTOBER 31, 2020

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	96.2	\$ 69,805.50
103	Cash Management	191.2	102,239.50
104	Communication with Interested Parties	26.7	19,698.00
105	U.S. Trustee / Court Reporting Requirements	20.0	10,389.50
106	Business Analysis & Operations	655.1	524,421.50
107	POR Development	48.4	30,733.00
109	Claims Process	21.8	12,531.00
110	Special Projects	40.8	21,337.00
113	Fee Statements and Fee Applications	32.3	16,816.50
114	Court Hearings	6.2	5,224.00
115	Forensic Analysis	34.6	30,357.50
		1,173.3	\$ 843,553.00
		Average Billing Rate	\$ 718.96

AlixPartners, LLP (“AlixPartners”), as financial advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Fourteenth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period October 1, 2020 through October 31, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 528] and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

[Remainder of page intentionally left blank.]

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$843,553.00, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$4.89, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$674,842.40 (80% of \$843,553.00) and expenses in the amount of \$4.89, for a total amount of \$674,847.29.

Dated: December 4, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/01/20	LJD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up and planning call.	0.70
10/01/20	JD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up and planning call.	0.70
10/01/20	JD	Review final KERP order.	0.20
10/01/20	HSB	Review documents and prepare agenda for status update call with AP team.	0.60
10/01/20	HSB	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up and planning call.	0.70
10/01/20	HSB	Review UCC motion to compel production of privileged documents	0.20
10/01/20	HSB	Review updated excel analysis prepared by S. Lemack (AlixPartners).	0.40
10/02/20	HSB	Review mediation order expanding scope of mediation	0.30
10/02/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	HSB	Prepare agenda and related notes for AlixPartners Team update call	0.30
10/02/20	HSB	Review KERP order and modified terms	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/02/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC and staffing update.	0.20
10/02/20	JD	Finalize latest HR file and send around for review.	1.00
10/02/20	LJD	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	SKL	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	NAS	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners) re: weekly team update call	0.50
10/02/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC and staffing update.	0.20
10/05/20	HSB	Prepare list of open items ahead of meeting with J. Lowne (Purdue)	0.30
10/05/20	HSB	Review KEIP/KERP motion for info ahead of upcoming hearing on keip and required supporting analysis	0.40
10/06/20	HSB	Call with M. Huebner, B. Kaminetzky, C. Robertson (all Davis Polk), J. Turner, T. Melvin (both PJT), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		weekly professionals planning call.	
10/06/20	HSB	Review Coventry APA	0.40
10/06/20	HSB	Review UCC diligence request list re: Purdue Aug Business Plan prepared by Province and related correspondence	0.20
10/06/20	JD	Call with M. Huebner, B. Kaminetzky, C. Robertson (all Davis Polk), J. Turner, T. Melvin (both PJT), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly professionals planning call.	0.30
10/06/20	LJD	Call with M. Huebner, B. Kaminetzky, C. Robertson (all Davis Polk), J. Turner, T. Melvin (both PJT), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly professionals planning call.	0.30
10/06/20	GJK	Call with M. Huebner, B. Kaminetzky, C. Robertson (all Davis Polk), J. Turner, T. Melvin (both PJT), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly professionals planning call.	0.30
10/07/20	HSB	Review board presentation from J. Lowne (Purdue) re: support for KEIP	0.40
10/07/20	HSB	Review summary of financial metrics and performance summary prepared by J. Lowne (Purdue)	0.20
10/07/20	HSB	Review UCC & NCSG motion re: examination of debtors' personnel	0.40
10/07/20	ADD	Review interested parties list and identify potential additions.	1.10
10/08/20	ADD	Review interested parties list and identify potential additions.	1.50
10/08/20	HSB	Weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/08/20	JD	Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update call.	0.60
10/08/20	GJK	Weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update call.	0.60
10/08/20	LJD	Weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update call.	0.60
10/09/20	LJD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/09/20	NAS	Prepare for weekly AlixPartners Purdue engagement team call.	0.70
10/09/20	NAS	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/09/20	SKL	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/09/20	GJK	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/09/20	JD	Prepare agenda for weekly AlixPartners call.	0.30
10/09/20	JD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/09/20	HSB	Prepare list of information required and supporting points for KEIP motion	0.60
10/09/20	HSB	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/09/20	LTN	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.60
10/12/20	ADD	Review interested parties list and identify additional names for October update.	2.60
10/12/20	JD	Review materials pulled together by PJT to be responsive to request for questions and materials for C. Landau (Purdue) deposition.	0.80
10/13/20	JD	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly update and planning call.	0.40
10/13/20	JD	Prepare agenda for weekly professional's call.	0.30
10/13/20	JD	Meeting with J. DelConte, S. Lemack and A. DePalma (all AlixPartners) re: trade claims analysis.	0.50
10/13/20	GJK	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly update and planning call.	0.40
10/13/20	LJD	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), L.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/13/20	SKL	Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly update and planning call.	0.50
10/13/20	ADD	Meeting with J. DelConte, S. Lemack and A. DePalma (all AlixPartners) re: trade claims analysis.	0.50
10/13/20	HSB	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), L. Donahue, G. Koch, H. Bhattal and J. DelConte (all AlixPartners) re: weekly update and planning call.	0.40
10/14/20	HSB	Update call with H. Bhattal, S. Lemack (both AlixPartners) to discuss case related issues and details.	0.50
10/14/20	HSB	Review list of financial questions prepared by PJT Partners for C. Landau (Purdue) deposition preparation	0.20
10/14/20	SKL	Update call with H. Bhattal, S. Lemack (both AlixPartners) to discuss case related issues and details.	0.50
10/14/20	SKL	Finalize updates to the cash and investment activity sections of the September MOR and circulate updates accordingly.	2.10
10/14/20	SKL	Finalize updates to the Restructuring Professional payment piece of the September MOR and circulate to C. MacDonald (Purdue) accordingly.	1.30
10/14/20	NAS	Review press around reported Purdue/DOJ settlement.	0.20
10/14/20	JD	Review and provide comments on the latest interested parties list and correspond with A. DePalma (AlixPartners) re: same.	0.50
10/14/20	JD	Prepare agenda for weekly update call with Purdue management tomorrow morning.	0.40
10/15/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	
10/15/20	JD	Prepare for update call with Purdue management.	0.30
10/15/20	LJD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.60
10/15/20	HSB	Review Aug 2020 Business Plan prepared by Purdue management.	0.80
10/15/20	HSB	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.60
10/16/20	HSB	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	HSB	Prepare notes and agenda for AlixPartners Team update call	0.40
10/16/20	HSB	Review debtor objection to UCC motion for production of privileged documents	0.20
10/16/20	ADD	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	LTN	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/16/20	KM	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	SKL	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	NAS	Review UCC motion to compel production of documents.	0.40
10/16/20	NAS	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	JD	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/16/20	JD	Review draft agenda for AlixPartners weekly call.	0.20
10/16/20	GJK	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly team update call	0.70
10/19/20	SKL	Prepare for and participate in discussion with C. MacDonald (Purdue) re: the September professional payment piece of the September Monthly Operating Report and prepare and circulate final version of the report.	1.40
10/19/20	SKL	Finalize 3rd quarter UST fee calculation and circulate to J. Lowne (Purdue) and H. Benson (Purdue) for payment.	0.60
10/20/20	SKL	Prepare latest prepetition payment detail and breakdown to be provided alongside September Monthly Operating Report detail to J. Lowne (Purdue).	0.70
10/20/20	SKL	Review and reconcile latest accounts payable debit inquiry provided by H. Benson (Purdue) and prepared update accordingly.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/20/20	GJK	Call with H. Bhattal, G. Koch, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case update and go forward planning.	0.40
10/20/20	JD	Call with H. Bhattal, G. Koch, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case update and go forward planning.	0.40
10/20/20	JD	Prepare agenda for weekly AlixPartners call.	0.30
10/20/20	HSB	Call with H. Bhattal, G. Koch, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case update and go forward planning.	0.40
10/21/20	HSB	Review draft of reply to KEIP Objections provided by D. Consla (Davis Polk)	1.30
10/21/20	HSB	Review financial reports and related presentations from Purdue and assessed information for inclusion in the reply to KEIP Objections	1.60
10/21/20	HSB	Prepared a draft marked up with edits and additional info for inclusion in the KEIP reply to Objections	1.40
10/21/20	SKL	Continue to prepare financial calculations to draft of reply to KEIP Objections.	0.50
10/21/20	SKL	Continue to review latest draft reply of KEIP Objections provided by DPW team and finalize financial calculations to be included.	2.30
10/21/20	SKL	Review August 2019 and August 2020 monthly flash report and prepare updated P&L comparisons to be included in the draft reply to KEIP Objections.	1.90
10/21/20	NAS	Review press coverage re: Purdue/DOJ settlement.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/22/20	NAS	Review Purdue Settlement Agreement with DOJ filed on docket.	1.30
10/22/20	SKL	Working session with H. Bhattal, (both AlixPartners) to finalize edits & related financial calculations for inclusion in draft of reply to KEIP Objections	1.60
10/22/20	SKL	Continue to review latest feedback provided re: reply to draft of KEIP Objections and prepare updates accordingly.	2.10
10/22/20	SKL	Finalize updates to financial metrics provided re: draft reply to KEIP objection and circulate to DPW team accordingly.	1.40
10/22/20	JD	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: weekly update and status call.	0.70
10/22/20	GJK	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: weekly update and status call.	0.70
10/22/20	HSB	Working session with H. Bhattal, S. Lemack (both AlixPartners) to finalize edits & related financial calculations for inclusion in draft of reply to KEIP Objections	1.60
10/22/20	HSB	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: weekly update and status call.	0.70
10/23/20	HSB	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen,	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/23/20	LTN	N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	KM	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	ADD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	GJK	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	JD	Review and provide comments on agenda for AlixPartners update call.	0.40
10/23/20	JD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	LJD	Review and comment on addendum to draft disclosures.	0.30
10/23/20	LJD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	SKL	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/23/20	NAS	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.60
10/27/20	LJD	Call with L. Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, D.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/27/20	GJK	Consla (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: weekly professionals' call.	1.00
10/27/20	JD	Prepare for and participate on call with L. Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, D. Consla (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: weekly professionals' call.	0.70
10/27/20	HSB	Call with L. Donahue, G. Koch, H. Bhattal, J. DelConte (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson, D. Consla (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: weekly professionals' call.	0.70
10/28/20	HSB	Review AdHoc Committee's motion re: DOJ Settlement	0.50
10/28/20	SKL	Meeting with S. Lemack L. Nguyen (both AlixPartners) to review latest OCP data provided by C. MacDonald (Purdue) and prepare updated report accordingly.	1.50
10/28/20	SKL	Meeting with C. MacDonald (Purdue) to discuss latest OCP activity report.	0.30
10/28/20	SKL	Finalize updates to the OCP report following meeting with C. MacDonald (Purdue) and circulate update accordingly.	0.80
10/29/20	SKL	Review and reconcile latest September financial report provided by E. Nowakowski (Purdue) and update September flash report accordingly.	2.40
10/29/20	SKL	Continue to finalize formatting and updates to the September flash report and circulate internally for final review and sign-off.	1.90
10/30/20	SKL	Finalize remaining updates to the September OCP report	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		and circulate to DPW accordingly.	
10/30/20	SKL	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	LJD	Review 13th monthly fee app	0.40
10/30/20	LJD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	SKL	Finalize remaining updates to the September flash report.	0.90
10/30/20	NAS	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	GJK	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	JD	Correspondence with Davis Polk re: UCC fee apps.	0.20
10/30/20	JD	Review and provide comments on weekly AlixPartners agenda.	0.20
10/30/20	JD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	HSB	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	LTN	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	ADD	Prepare for weekly AlixPartners Purdue engagement team update call.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/30/20	ADD	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
10/30/20	KM	Call with H. Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.80
Total			96.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	8.20	515.00	4,223.00
Sam K Lemack	28.90	515.00	14,883.50
Lan T Nguyen	2.70	515.00	1,390.50
Nate A Simon	6.10	515.00	3,141.50
Sam J Canniff	0.50	645.00	322.50
Gabe J Koch	6.80	840.00	5,712.00
HS Bhattal	21.00	840.00	17,640.00
Jesse DelConte	13.40	950.00	12,730.00
Kevin M McCafferty	2.10	950.00	1,995.00
Lisa Donahue	6.50	1,195.00	7,767.50
Total Hours & Fees	96.20		69,805.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/01/20	ADD	Meeting with S. Lemack, A. DePalma and L. Nguyen (all AlixPartners) to discuss and make updates to the Restructuring Professional and Retained Professional trackers.	0.60
10/01/20	LTN	Meeting with S. Lemack, A. DePalma and L. Nguyen (all AlixPartners) to discuss and make updates to the Restructuring Professional and Retained Professional trackers.	0.60
10/01/20	LTN	Review the latest application fees filed from the docket to update the Restructuring Professional and Retained Professional trackers.	1.80
10/01/20	SKL	Meeting with S. Lemack, A. DePalma and L. Nguyen (all AlixPartners) to discuss and make updates to the Restructuring Professional and Retained Professional trackers.	0.60
10/01/20	SKL	Prepare for and participate in discussion with R. Haberlin (Purdue) to discuss latest critical vendor payment inquiry and next steps.	0.80
10/01/20	SKL	Create accounts payable release file.	0.70
10/02/20	SKL	Create accounts payable release file.	0.70
10/02/20	SKL	Finalize remaining updates to the Purdue cash summary and update latest Purdue forecast accordingly.	2.00
10/02/20	SKL	Finalize remaining updates to the Rhodes cash summary and update latest Rhodes forecast accordingly.	1.70
10/05/20	SKL	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to discuss latest cash activity and begin preparing the week ended 10/02 cash report.	2.00
10/05/20	SKL	Finalize updates to the Restructuring professional fee tracker prior to updating the latest cash forecast.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/05/20	SKL	Finalize review of EastWest transactions and update categories of weekly cash report accordingly.	2.10
10/05/20	SKL	Finalize review of Paysource transactions and update categories of weekly cash report accordingly.	1.90
10/05/20	SKL	Update IAC cash summaries and prepare open items for E. Nowakowski and T. Gabriele (both Purdue) to review.	1.10
10/05/20	SKL	Create accounts payable release file.	0.70
10/05/20	LTN	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to discuss latest cash activity and begin preparing the week ended 10/02 cash report.	2.00
10/05/20	HSB	Review weekly cash report (week ended 9/25) prepared by S. Lemack (AlixPartners) and provided comments.	0.80
10/05/20	ADD	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to discuss latest cash activity and begin preparing the week ended 10/02 cash report.	2.00
10/06/20	ADD	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to continue discussion re: latest cash activity and follow-up items.	0.90
10/06/20	LTN	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to continue discussion re: latest cash activity and follow-up items.	0.90
10/06/20	LTN	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to review latest sales forecast provided by J. Knight (Purdue) and begin updating the latest 13-week Purdue cash forecast.	2.60
10/06/20	LTN	Meeting with L. Nguyen and S. Lemack (all AlixPartners) to continue discussion on the latest Purdue 13-week forecast and make additional updates accordingly.	0.90
10/06/20	SKL	Create accounts payable release file.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/06/20	SKL	Finalize updates to the Retained professional fee tracker prior to updating the latest cash forecast.	1.20
10/06/20	SKL	Prepare updated AP file to implement into the Operating Expense section of the latest cash forecasts.	1.20
10/06/20	SKL	Prepare updated AR file to implement into the Customer Receipt section of the latest cash forecasts.	0.90
10/06/20	SKL	Meeting with A. DePalma, L. Nguyen and S. Lemack (all AlixPartners) to continue discussion re: latest cash activity and follow-up items.	0.90
10/06/20	SKL	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to review latest sales forecast provided by J. Knight (Purdue) and begin updating the latest 13-week Purdue cash forecast.	2.60
10/06/20	SKL	Meeting with L. Nguyen and S. Lemack (all AlixPartners) to continue discussion on the latest Purdue 13-week forecast and make additional updates accordingly.	0.90
10/06/20	SKL	Prepare for and participate in critical vendor discussion with R. Haberlin (Purdue).	0.60
10/07/20	SKL	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to review the latest Rhodes 13-week cash forecast and update the Operating Expense section of the cash forecast accordingly.	2.20
10/07/20	SKL	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to review the latest Rhodes 13-week cash forecast and update the Customer Receipt section of the cash forecast accordingly.	1.40
10/07/20	SKL	Implement the latest Restructuring and Retained professional fee trackers into the Purdue 13-week cash forecast.	1.30
10/07/20	SKL	Finalize updates to the Operating Expense section of the	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		latest 13-week Purdue cash forecast.	
10/07/20	SKL	Create accounts payable release file.	0.60
10/07/20	SKL	Finalize updates to the Customer Receipt section of the latest 13-week Purdue cash forecast.	1.10
10/07/20	LTN	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to review the latest Rhodes 13-week cash forecast and update the Operating Expense section of the cash forecast accordingly.	2.20
10/07/20	LTN	Meeting with S. Lemack (all AlixPartners) to review the latest Rhodes 13-week cash forecast and update the Customer Receipt section of the cash forecast accordingly	1.40
10/07/20	JD	Review and provide comments on the latest forecast to actual reporting package.	0.50
10/08/20	SKL	Create accounts payable release file.	0.70
10/08/20	SKL	Finalize updates to the Operating Expense section of the latest Rhodes 13-week cash forecast.	2.30
10/09/20	SKL	Finalize updates to the Customer Receipt section of the latest Rhodes 13-week cash forecast.	1.30
10/09/20	SKL	Review the latest Customer Rebate tracker provided by D. Krishnan (Purdue) and update the Purdue 13-week cash forecast.	1.40
10/09/20	SKL	Create accounts payable release file.	0.70
10/09/20	SKL	Finalize updates to the Customer Receipt section of the Rhodes cash forecast.	1.40
10/09/20	SKL	Finalize remaining updates to the latest 13-week cash forecast deck and circulate internally for review and sign-off.	1.50
10/09/20	SKL	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to discuss and finalize updates to the	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Rhodes cash forecast.	
10/09/20	LTN	Meeting with L. Nguyen and S. Lemack (both AlixPartners) to discuss and finalize updates to the Rhodes cash forecast.	0.30
10/09/20	HSB	Review updated 13-week cash forecast prepared by S. Lemack (AlixPartners) for Purdue & Rhodes	1.30
10/12/20	HSB	Review email from S. Lemack (AlixPartners) in response to comments on cash report	0.10
10/12/20	HSB	Continue reviewing 13-week cash forecast and emailed comments to S. Lemack (AlixPartners)	0.20
10/12/20	SKL	Create accounts payable release file.	0.80
10/12/20	SKL	Finalize updates to the August flash report and circulate internally for final sign-off.	1.80
10/12/20	SKL	Review latest Purdue financial board presentation provided by E. Nowakowski (Purdue) and begin preparing August flash report accordingly.	2.10
10/13/20	SKL	Review latest feedback provided re: 13-week cash forecast and prepare and circulate updated file accordingly.	1.60
10/13/20	SKL	Review latest feedback provided re: August flash report and circulate file for final review and sign-off.	0.70
10/13/20	SKL	Review latest critical vendor feedback provided by R. Haberlin (Purdue) and circulate update accordingly.	0.70
10/13/20	SKL	Create accounts payable release file.	0.70
10/13/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates re: Paysource cash transactions.	0.60
10/13/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates re: Paysource cash	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		transactions.	
10/13/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 10.09 cash report	2.20
10/13/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 10.09 cash report	2.00
10/13/20	LTN	Reconcile Bank Account Summary for the week ended 10.09 cash report	1.80
10/13/20	HSB	Review Aug 2020 Flash report prepared by S. Lemack (AlixPartners).	1.60
10/13/20	HSB	Review Aug Financial Statement (full deck) prepared by J. Lowne (Purdue)	1.20
10/14/20	HSB	Review KERP amounts for purposes of inclusion in weekly cash forecasts	0.20
10/14/20	HSB	Review updates to 13-week cash forecast prepared by S. Lemack (AlixPartners) for Purdue & Rhodes	0.10
10/14/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss and prepare the monthly breakdown of cash disbursements/receipts.	1.40
10/14/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss and prepare the monthly bank account balances and investment activity report.	1.20
10/14/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss and prepare the monthly Restructuring Professional payment schedule.	1.20
10/14/20	LTN	Prepare the Purdue and Rhodes IAC cash summaries and updates to the deck accordingly	1.80
10/14/20	LTN	Reconcile the latest IAC transactions and prepared the updated IAC Summaries	1.60
10/14/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		discuss and prepare the monthly breakdown of cash disbursements/receipts.	
10/14/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss and prepare the monthly bank account balances and investment activity report.	1.20
10/14/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss and prepare the monthly Restructuring Professional payment schedule.	1.20
10/14/20	SKL	Create accounts payable release file.	0.60
10/15/20	SKL	Create accounts payable release file.	1.20
10/15/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and reconcile the latest Purdue investment activity report and prepare updates to the investment piece of the cash actuals report accordingly.	1.90
10/15/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to continue to reconcile the Purdue investment activity, latest IAC cash activity, and send follow-up inquiries to J. Liceaga (TXP) and T. Gabriele (Purdue) accordingly.	1.50
10/15/20	LTN	Reconcile the latest Purdue investment activities and updated the weekly cash report.	1.20
10/15/20	LTN	Review the latest feedback provided re: rebates, IAC transactions and updated the weekly cash report.	1.60
10/15/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and reconcile the latest Purdue investment activity report and prepare updates to the investment piece of the cash actuals report accordingly.	1.90
10/15/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to continue to reconcile the Purdue investment activity, latest IAC cash activity, and send follow-up inquiries to J. Liceaga (TXP) and T. Gabriele (Purdue) accordingly.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/15/20	HSB	Review updated draft of 13-week cash flow forecast prepared by S. Lemack (AlixPartners) for Purdue & Rhodes	0.10
10/15/20	HSB	Review weekly cash report (week ended 10/2) prepared by S. Lemack (AlixPartners) for Purdue & Rhodes	0.70
10/16/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest updates to the Purdue forecast-to-actuals variance and prepare updates accordingly.	0.40
10/16/20	LTN	Finalize updates to the Purdue and Rhodes cash summaries and prepared the updated weekly cash report deck.	1.80
10/16/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for the week ended 10.09 and updated the weekly cash report deck	2.20
10/16/20	LTN	Prepare the latest Rhodes forecast to actual variance analysis for the week ended 10.09 and updated the weekly cash report deck.	2.00
10/16/20	LTN	Finalize updates to the weekly cash report deck for the week ended 10.09 and circulated internally for sign-off.	2.40
10/16/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest updates to the Purdue forecast-to-actuals variance and prepare updates accordingly.	0.40
10/16/20	SKL	Finalize review of EastWest cash transactions and updated categorizations accordingly.	1.70
10/16/20	SKL	Finalize Purdue and Rhodes forecast-to-actuals variance analysis and updated the cash report accordingly.	1.70
10/16/20	SKL	Create accounts payable release file.	0.70
10/16/20	SKL	Prepare 3rd quarter US Trustee calculation based on Q3 debtor disbursements.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/16/20	SKL	Finalize updates to the week ended 10/16 weekly cash report and circulate updated deck accordingly.	1.00
10/19/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and finalize updates re: week ended 10/09 cash report.	0.90
10/19/20	SKL	Create accounts payable release file.	0.70
10/19/20	SKL	Review and reconcile latest Purdue investment activity report provided by T. Gabriele (Purdue) and J. Liceaga (TXP).	1.70
10/19/20	SKL	Pull latest Paysource transactions report and begin implementation into the week ended 10/16 cash report.	0.50
10/19/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and finalize updates re: week ended 10/09 cash report.	0.90
10/19/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 10.16 cash report	1.80
10/19/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 10.16 cash report	2.00
10/19/20	LTN	Update new vendors from the Paysource transactions	0.80
10/19/20	HSB	Review weekly cash report (week ended 10/9) prepared by L. Nguyen (AlixPartners) for Purdue & Rhodes	0.70
10/20/20	LTN	Prepare the detailed and summary cash report for Purdue & Rhodes entities for the week ended 10.16	1.50
10/20/20	LTN	Prepare the IAC cash transactions for Purdue & Rhodes entities for the week ended 10.16	1.10
10/20/20	LTN	Prepare the IAC transaction summary for the week ended 10.16 cash report	0.50
10/20/20	SKL	Finalize remaining updates to the week ended 10/09 cash report and circulate to J. Lowne (Purdue) and R. Aleali	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		(Purdue) accordingly.	
10/20/20	SKL	Create accounts payable release file.	0.70
10/21/20	SKL	Create accounts payable release file.	0.70
10/21/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest EastWest cash report and categorize cash transactions accordingly.	0.80
10/21/20	LTN	Prepare a list of rebates transactions to C. Hobbick (Purdue) and finalized updates accordingly	0.90
10/21/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest EastWest cash report and categorize cash transactions accordingly.	0.80
10/21/20	LTN	Prepare a list of uncategorized cash transactions to E. Nowakowski and R. Brown (both Purdue), and finalized updates accordingly	1.10
10/22/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for week ended 10.16 and updated the weekly cash report deck	1.80
10/22/20	LTN	Prepare the latest Rhodes forecast to actual variance analysis for week ended 10.16 and updated the weekly cash report deck	1.70
10/22/20	SKL	Create accounts payable release file.	0.70
10/23/20	SKL	Create accounts payable release file.	0.60
10/23/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates to the week ended 10/16 cash report.	0.80
10/23/20	SKL	Review latest feedback provided by R. Brown (Purdue) and ensure updates are captured in the latest IAC cash summary.	1.60
10/23/20	SKL	Review latest feedback provided re: Rhodes forecast-to-	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		actuals variances and ensure they're captured accordingly in the week ended 10/16 cash report.	
10/23/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates to the week ended 10/16 cash report.	0.80
10/23/20	LTN	Finalize the updates to Purdue cash forecast and updated slides for 10.16 deck	1.30
10/23/20	LTN	Finalize the updates to Rhodes cash forecast and updated slides for 10.16 deck	1.00
10/26/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates and feedback re: week ended 10/16 cash report.	0.90
10/26/20	LTN	Investigate the forecast and actual variance and sent queries to E. Nowakowski (Purdue) and updated the weekly report accordingly	1.40
10/26/20	LTN	Finalize updates to the weekly cash report deck for the week ended 10.16 and circulate for internal sign-off	0.90
10/26/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 10.23 cash report	1.90
10/26/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 10/16/2020.	0.60
10/26/20	SKL	Review final updates made to the week ended 10/16 cash report and provide notes and feedback accordingly.	2.20
10/26/20	SKL	Finalize review of Purdue and Rhodes forecast-to-actuals variances and circulate updates accordingly.	1.30
10/26/20	SKL	Prepare vendor AP and payment breakdown per H. Benson (Purdue) request.	0.50
10/26/20	SKL	Prepare and review latest Paysource transactions report and circulate accordingly.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
10/26/20	SKL	Create accounts payable release file.	0.70
10/26/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates and feedback re: week ended 10/16 cash report.	0.90
10/27/20	SKL	Finalize review of latest critical vendor inquiry and prepare updated breakdown for R. Haberin (Purdue) and E. Ruiz (Purdue).	0.80
10/27/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest open items re: week ended 10/23 cash report.	0.40
10/27/20	SKL	Create accounts payable release file.	0.90
10/27/20	LTN	Reconcile the latest IAC transactions and prepared the updated IAC Summaries for week ended 10.23 cash report	1.60
10/27/20	LTN	Prepare the detailed and summary cash report for Purdue & Rhodes entities for the week ended 10.23	1.90
10/27/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest open items re: week ended 10/23 cash report.	0.40
10/27/20	LTN	Review the latest weekly cash report and prepare a list of open cash transactions	1.70
10/27/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 10.23 cash report	2.10
10/28/20	LTN	Review feedbacks for open transactions and updated the week ended 10.23 cash report accordingly	1.00
10/28/20	LTN	Review feedbacks provided by (Purdue), updated the 10.16 deck and circulated to J. Lowne (Purdue) for final sign-off	1.30
10/28/20	LTN	Prepare the latest Purdue forecast to actual variance	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		analysis for week ended 10.23	
10/28/20	SKL	Create accounts payable release file.	0.80
10/28/20	SKL	Finalize review of open items re: week ended 10/16 cash actuals and circulate to E. Nowakowski (Purdue) accordingly.	1.20
10/28/20	SKL	Review and reconcile Purdue weekly sales report by E. Nowakowski (Purdue) and update accordingly.	0.90
10/29/20	SKL	Create accounts payable release file.	0.90
10/29/20	JD	Review and provide comments on weekly cash report.	0.40
10/29/20	LTN	Continue to update the latest Purdue forecast to actual variance analysis for week ended 10.23 and explain the variances	1.60
10/29/20	LTN	Review feedbacks provided by R. Brown, C. Hobbick and T. Gabriele (Purdue) and updated the cash report accordingly	0.90
10/29/20	HSB	Review Sept board deck prepared by J. Lowne (Purdue)	0.60
10/29/20	HSB	Review draft of OCP Report (for September 2020)	0.40
10/30/20	HSB	Review draft of monthly flash report prepared by S. Lemack (AlixPartners) for the month of Sept 2020.	0.60
10/30/20	HSB	Continue reviewing Sept board deck prepared by J. Lowne (Purdue)	1.20
10/30/20	LTN	Finalize the latest Purdue & Rhodes forecast to actual variance analysis for week ended 10.23 and updated the weekly cash report deck	1.60
10/30/20	LTN	Finalize deck for the weekly cash report for week ended 10.23 and circulate for the internal review	1.10
10/30/20	SKL	Create accounts payable release file.	0.60
10/30/20	SKL	Review latest variances re: Purdue forecast-to-actuals	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		and circulate update internally.	
10/30/20	SKL	Review latest variances re: Rhodes forecast-to-actuals and circulate update internally.	0.80
10/30/20	SKL	Finalize review and updates to the week ended 10/23 cash report and circulate update internally.	1.70
Total			191.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	3.50	515.00	1,802.50
Sam K Lemack	95.70	515.00	49,285.50
Lan T Nguyen	80.70	515.00	41,560.50
HS Bhattal	10.40	840.00	8,736.00
Jesse DelConte	0.90	950.00	855.00
Total Hours & Fees	191.20		102,239.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/05/20	JD	Review latest diligence request from Province in relation to files being pulled together for the August business plan refresh.	0.50
10/05/20	JD	Call with M. Atkinson (Province) re: KEIP proposal.	0.30
10/05/20	JD	Review AG settlement response from the company for the UCC.	0.40
10/05/20	JD	Review request from the AHC for access to certain materials to share with their clients.	0.30
10/05/20	JD	Review request from Side B for access to data room materials.	0.40
10/06/20	ADD	Compile and prepare documents to send to the Davis Polk eDiscovery team for processing and upload to the data room.	1.30
10/07/20	ADD	Compile and prepare documents to send to the Davis Polk eDiscovery team for processing and upload to the data room.	1.70
10/11/20	JD	Correspondence with Davis Polk, Province and Willis Towers Watson re: diligence question from Province on KEIP/KERP analysis figures.	0.50
10/11/20	JD	Prepare annualized retention analysis and correspondence with Davis Polk and Willis Towers re: same.	0.80
10/12/20	JD	Check in on responses to open FTI diligence questions after FTI follow up.	0.30
10/12/20	JD	Review and provide comments on analysis from PJT re: request from M. Kesselman (Purdue) in response to open questions from state AGs.	0.60
10/12/20	ADD	Prepare diligence production for upload to the data room for the creditor committees' review.	2.10
10/13/20	ADD	Upload diligence production to the data room for the	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		creditor committee's review.	
10/13/20	ADD	Prepare diligence production for upload to the data room for the creditor committees' review.	1.20
10/13/20	ADD	Review diligence request and follow up with outstanding items.	1.30
10/14/20	JD	Call with M. Burke, K. Borgerding, M. Patel (all BTCP Pharma), J. Leedy (Examoto), J. Ducharme, R. Fanelli, C. George, M. Kwarcinski, S. Daniel (all Purdue), J. Turner, T. Melvin (all PJT) re: REMS discussion.	1.10
10/14/20	JD	Review summary headcount breakdown from Skadden for discussions with DOJ.	0.80
10/14/20	JD	Review BTCP pharma slides in advance of call.	0.30
10/14/20	JD	Review latest Nalmefene report to be shared with creditor advisors and correspondence with Purdue management and Davis Polk re: same.	0.40
10/14/20	JD	Correspondence with Skadden re: roster breakdown follow up questions.	0.40
10/15/20	ADD	Research document data room productions and provide requested material to DPW.	0.90
10/15/20	ADD	Review information sharing protocol from creditor group and updated draft sharing tracker.	0.60
10/16/20	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.30
10/19/20	JD	Call with S. Gilbert (Gilbert), K. Eckstein (Kramer Levin), S. Burian, G. Coutts (both Houlihan), J. Turner, T. Melvin (both PJT), M. Kesselman (Purdue), M. Huebner, E. Vonnegut, W. Curran, W. Taylor (all Davis Polk) re: post-emergence governance and tax discussions.	1.10
10/19/20	ADD	Search data room productions for documents requested by DPW	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/20/20	JD	Correspondence with Purdue and Davis Polk re: KEIP analysis and response.	0.80
10/22/20	JD	Correspondence with FTI, Province, PJT and Purdue management re: pipeline planning call next week.	0.40
10/23/20	ADD	Review data room for document requested by FTI.	0.30
10/26/20	JD	Correspondence with FTI and Davis Polk re: Special Committee diligence materials.	0.30
10/26/20	JD	Correspondence with Province re: open KEIP diligence questions.	0.30
10/26/20	JD	Correspondence with A. DePalma (AlixPartners) and PJT re: open FTI pipeline diligence questions.	0.40
10/27/20	JD	Prepare for and participate in call with M. Diaz, B. Bromberg, E. Suric (all FTI), M. Atkinson, J. Crockett (both Province), L. Szlezinger, K. Sheridan (all Jefferies), G. Coutts, H. Schenk (both Houlihan), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, V. Mancinelli, D. Fogel, R. Fanelli, M. Ronning, J. Ducharme (all Purdue) re: pipeline update.	0.90
10/27/20	JD	Review and provide comments on draft diligence responses from the company prior to the pipeline call.	0.50
10/27/20	HSB	Prepare for and participate in call with M. Diaz, B. Bromberg, E. Suric (all FTI), M. Atkinson, J. Crockett (both Province), L. Szlezinger, K. Sheridan (all Jefferies), G. Coutts, H. Schenk (both Houlihan), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, V. Mancinelli, D. Fogel, R. Fanelli, M. Ronning, J. Ducharme (all Purdue) re: pipeline update.	0.90
10/28/20	ADD	Call with Davis Polk diligence team re: diligence requests.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/29/20	ADD	Review outstanding diligence requests and request responsive materials.	1.10
10/29/20	JD	Review presentation from the AHC advisors re: organizational structure.	0.50
10/29/20	JD	Correspondence with Province re: open diligence questions.	0.40
Total			26.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	12.80	515.00	6,592.00
HS Bhattal	0.90	840.00	756.00
Jesse DelConte	13.00	950.00	12,350.00
Total Hours & Fees	26.70		19,698.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/12/20	NAS	Meeting with L. Nguyen, N. Simon (both AlixPartners) to discuss insider payment MOR and begin preparing the MOR for September 2020	0.80
10/12/20	NAS	Request September MOR insider payments information and review data received.	1.40
10/12/20	LTN	Meeting with L. Nguyen, N. Simon (both AlixPartners) to discuss insider payment MOR and begin preparing the MOR for September 2020	0.80
10/14/20	NAS	Review MOR insider payments data related to indemnification.	0.40
10/15/20	NAS	Work session with L. Nguyen, N. Simon (both AlixPartners) to build final insider payments section of September 2020 MOR.	1.00
10/15/20	NAS	Review insider payments section of September 2020 MOR for accuracy.	0.40
10/15/20	LTN	Work session with L. Nguyen, N. Simon (both AlixPartners) to build final insider payments section of September 2020 MOR.	1.00
10/15/20	ADD	Review September MOR Debtor Questionnaire and follow up Davis Polk re: potential updates from previous months.	0.40
10/15/20	ADD	Review interested parties list and identify additional names for October updates	0.70
10/16/20	NAS	Check insider payments section of September 2020 MOR for accuracy.	0.70
10/16/20	ED	Process disclosures for the six month supplemental.	2.50
10/19/20	KAS	Email E. DuHalde (AlixPartners) re: party in interest and corresponding disclosure.	0.30
10/20/20	JD	Correspondence with J. Lowne, H. Benson (all Purdue)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		and S. Lemack (AlixPartners) re: US Trustee payments.	
10/20/20	ADD	Meeting with A. DePalma, L. Nguyen (both AlixPartners) to discuss the MOR process	0.80
10/20/20	LTN	Meeting with A. DePalma, L. Nguyen (both AlixPartners) to discuss the MOR process	0.80
10/21/20	LTN	Meeting with L. Nguyen, A. DePalma (both AlixPartners) to discuss updates to Sep MOR	0.80
10/21/20	ADD	Prepare September monthly operating report for client review, signature and upload.	1.60
10/21/20	ADD	Meeting with L. Nguyen, A. DePalma (both AlixPartners) to discuss updates to Sep MOR	0.80
10/21/20	JD	Review draft September financials for the monthly operating report.	0.20
10/21/20	JD	Review correspondence with R. Aleali, C. Ricarte, J. Lowne (all Purdue) re: open MOR questions.	0.30
10/28/20	LTN	Meeting with S. Lemack L. Nguyen (both AlixPartners) to review latest OCP data provided by C. MacDonald (Purdue) and prepare updated report accordingly.	1.50
10/29/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to finalize review of OCP report and discuss updates to the September flash report.	1.10
10/29/20	JD	Review ordinary course professional summary report prior to sending to Davis Polk.	0.30
10/29/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to finalize review of OCP report and discuss updates to the September flash report.	1.10
Total			20.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Edward Duhalde	2.50	360.00	900.00
Kaitlyn A Sundt	0.30	510.00	153.00
Andrew D DePalma	4.30	515.00	2,214.50
Sam K Lemack	1.10	515.00	566.50
Lan T Nguyen	6.00	515.00	3,090.00
Nate A Simon	4.70	515.00	2,420.50
Jesse DelConte	1.10	950.00	1,045.00
Total Hours & Fees	20.00		10,389.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/01/20	GJK	Plan and coordinate Mundipharma diligence.	2.00
10/01/20	GJK	Review Mundipharma country level product tables for report.	2.00
10/01/20	NAS	Build automated Appendix tables for Balance Sheet and Cash Flow Statement in Mundipharma model.	1.20
10/01/20	NAS	Build automated Appendix tables for Analgesics products in Mundipharma model.	1.20
10/01/20	NAS	Build automated Appendix tables for Europe region in Mundipharma model.	1.40
10/01/20	NAS	Build automated Appendix tables for LAM region in Mundipharma model.	1.10
10/01/20	NAS	Review recent news related to Purdue Canada litigation.	0.40
10/01/20	NAS	Build automated Appendix tables for select market/product pairs in Mundipharma model.	1.10
10/01/20	JD	Call with J. Lowne (Purdue) re: portfolio committee update.	0.30
10/01/20	JD	Call with J. Lowne, D. Rosen, M. Ronning, K. Gadske (all Purdue), J. Turner, T. Melvin (both PJT), M. Atkinson (Province), M. Diaz, B. Bromberg, E. Suric (all FTI), B. Troester, K. Sheridan (both Jefferies) re: OxyContin forecast.	0.70
10/01/20	JD	Correspondence with Province re: pension plan.	0.30
10/01/20	JD	Review OxyContin sensitivity presentation from FTI prior to call this afternoon.	0.30
10/01/20	JD	Review portfolio committee presentation.	0.40
10/01/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Rhodes transition touch base.	0.50
10/01/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano, supply chain (all Purdue) re: Project Catalyst	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/01/20	ADD	Transition Team Meeting Supply Chain Meeting with R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta, B. Evans, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain.	0.60
10/01/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	0.60
10/01/20	ADD	Meeting with J. Doyle, E. Ruta, K. McCarthy (all Purdue), M. Gibson, A. Gallogly (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract review.	0.40
10/01/20	KM	Meeting with J. Doyle, E. Ruta, K. McCarthy (all Purdue), M. Gibson, A. Gallogly (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract review.	0.40
10/01/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	0.60
10/01/20	KM	Correspondence re: Catalyst transition workstreams.	0.30
10/01/20	JD	Review updates on managed care coverage.	0.20
10/01/20	JD	Review final file detailing bonus accrual accounting.	0.30
10/01/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Rhodes transition touch base.	0.50
10/01/20	KM	Activity tracking and transition planning re: Catalyst transition workstreams.	2.60
10/01/20	KM	Meeting with R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta, B. Evans, J. Giordano (all Purdue), and A. DePalma, K.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners) re: Catalyst transition - supply chain.	
10/01/20	KM	Develop dashboard re: project Catalyst.	0.50
10/01/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano, supply chain (all Purdue) re: Project Catalyst Transition Team Meeting Supply Chain	1.30
10/01/20	KM	Update milestone tracking tools re: project Catalyst.	1.80
10/02/20	JD	Prepare for and participate in call with J. Lowne, C. DeStefano, E. Nowakowski (all Purdue) re: bonus accounting.	0.30
10/02/20	JD	Review HRT update presentation to share with creditors.	0.40
10/02/20	JD	Review status update on Project Catalyst work stream.	0.20
10/02/20	JD	Review agenda for AlixPartners update call.	0.20
10/02/20	KM	Analysis and dashboard tracking re: project Catalyst transition.	2.40
10/02/20	KM	Call with K. Kolar (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst tech transfer planning for Rhodes Pharma.	1.20
10/02/20	KM	Update milestones re: tech transfers for Rhodes Pharma.	0.60
10/02/20	KM	Team planning and correspondence re: Catalyst transition planning.	0.80
10/02/20	KM	Analysis re: projected Catalyst savings.	0.80
10/02/20	KM	Analysis and dashboard tracking re: project Catalyst transition.	1.20
10/02/20	GJK	Review Mundipharma diligence updates to advisor questions.	2.00
10/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review Appendix of draft Mundipharma diligence report.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review Appendix of draft Mundipharma diligence report.	0.50
10/02/20	GJK	Plan and coordinate Mundipharma diligence.	2.00
10/02/20	NAS	Review new diligence files provided by Huron/Mundipharma.	1.20
10/02/20	NAS	Review prior Key Findings section of draft Mundipharma diligence report.	0.70
10/05/20	NAS	Review Key Findings section of draft Mundipharma diligence report.	1.30
10/05/20	NAS	Review new diligence files and information provided by Huron/Mundipharma.	1.10
10/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss follow-up correspondence with Huron/Mundipharma.	0.40
10/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review potential revisions to Key Findings section of draft Mundipharma diligence report.	1.00
10/05/20	NAS	Review Mundipharma OpEx incurred by smaller markets.	2.00
10/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss follow-up correspondence with Huron/Mundipharma.	0.40
10/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review potential revisions to Key Findings section of draft Mundipharma diligence report.	1.00
10/05/20	GJK	Plan and coordinate Mundipharma report updates.	2.00
10/05/20	GJK	Review Huron diligence updates.	1.50
10/05/20	GJK	Outline potential upside scenarios to Mundipharma plan.	1.00
10/05/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.30
10/05/20	KM	Call with J. Giordano (Purdue) re: Catalyst transition.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/05/20	KM	Call with E. Ruta (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: contracts review.	0.40
10/05/20	KM	Update smartsheet tracking re: Catalyst contracts.	0.90
10/05/20	KM	Analysis re: critical lab equipment and support vendors.	1.70
10/05/20	KM	Meeting with S. Yates, S. Aschmann, M. Mancinelli, R. Shamblen, J. Northington, B. Purdon, D. McGuire, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	1.10
10/05/20	KM	Update workstream re: quality systems transition for Catalyst.	1.30
10/05/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Noramco qualifications and tech transfers.	1.20
10/05/20	KM	Update transitions workstreams re: project Catalyst.	1.30
10/05/20	JD	Call with C. DeStefano and D. Warren (both Purdue) re: KERP calculation data.	0.60
10/05/20	JD	Begin preparing summary KERP file outlining the calculations for all of the KERP payments for internal Purdue HR.	1.80
10/05/20	JD	Finalize KERP summary document for HR.	1.60
10/05/20	JD	Call with J. Turner, J. O'Connell (both PJT), M. Kesselman (Purdue) and M. Huebner (Davis Polk) re: BCTP Pharma.	0.50
10/05/20	JD	Review KERP calculation data for specific individuals per company request. Prepare for call with company.	0.70
10/05/20	JD	Update latest professional fee actuals and forecast to share with Davis Polk.	1.10
10/05/20	ADD	Update liabilities subject to compromise spreadsheet for	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		September month-end.	
10/05/20	ADD	Review Intralinks invoice and excessive pages uploaded in September.	0.40
10/05/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Noramco qualifications and tech transfers.	1.20
10/05/20	ADD	Meeting with S. Yates, S. Aschmann, M. Mancinelli, R. Shamblen, J. Northington, B. Purdon, D. McGuire, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	1.10
10/05/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.30
10/05/20	ADD	Call with E. Ruta (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: contracts review.	0.40
10/06/20	ADD	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: Smartsheet setup for dashboard reporting.	0.50
10/06/20	ADD	Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Waltz, J. Gibbs, E. Ruta, B. Evans, J. Fox, D. McGuire, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain workstream.	1.00
10/06/20	ADD	Call with J. Northington (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Quality working session.	1.00
10/06/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		operations.	
10/06/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.20
10/06/20	ADD	Working session with K. Kolar, J. Waltz (both Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Rhodes Pharma tech transfers.	1.00
10/06/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: catch up re: contracts and other workstreams.	0.40
10/06/20	JD	Review latest liabilities subject to compromise summary.	0.30
10/06/20	JD	Call with W. Taylor, A. Lele, C. Robertson (all Davis Polk), M. Florence, J. Bragg (both Skadden), R. Aleali, K. McCarthy, B. Miller (all Purdue), T. Melvin, G. Sim (both PJT) re: material contract review and trust transfer process.	1.00
10/06/20	JD	Review updated details from D. Warren (Purdue) re: attestation list. Correspondence re: same.	0.40
10/06/20	JD	Correspondence with M. Atkinson (Province) and R. Collura (AlixPartners) re: investigation diligence questions.	0.30
10/06/20	JD	Review correspondence from Davis Polk re: BTCP Pharma discussions.	0.30
10/06/20	JD	Review potential balance sheet footnote re: settlement accruals.	0.30
10/06/20	JD	Review KEIP/KERP presentation from Willis Towers Watson in regards to certain questions from the UCC.	0.60
10/06/20	JD	Review the previously filed declaration and compensation comparable analysis from last year.	0.50
10/06/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: catch up re: contracts and other workstreams.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/06/20	JD	Correspondence with M. Huebner, E. Vonnegut (both Davis Polk) and M. Kesselman (Purdue) re: counter proposals from the UCC re: KEIP.	0.70
10/06/20	JD	Review status of diligence responses to outstanding requests from Province.	0.60
10/06/20	JD	Correspondence with C. DeStefano (Purdue) re: KERP calculations.	0.20
10/06/20	JD	Finalize list of KERP recipients and compare it to the list from management. Investigate details of differences and correspondence with C. DeStefano and D. Warren (both Purdue) re: same.	2.00
10/06/20	JD	Call with K. McCafferty and J. DelConte (both AlixPartners) re: Rhodes Tech transition timeline.	0.30
10/06/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.20
10/06/20	KM	Update workstream milestones re: project Catalyst tech transfer activities.	1.50
10/06/20	KM	Working session with K. Kolar, J. Waltz (both Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Rhodes Pharma tech transfers.	1.00
10/06/20	KM	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: Smartsheet setup for dashboard reporting.	0.50
10/06/20	KM	Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Waltz, J. Gibbs, E. Ruta, B. Evans, J. Fox, D. McGuire, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain workstream.	1.00
10/06/20	KM	Call with J. Northington (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition -	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Quality working session.	
10/06/20	KM	Update workstream milestones re: project Catalyst quality activities.	2.20
10/06/20	KM	Call with K. McCafferty and J. DelConte (both AlixPartners) re: Rhodes Tech transition timeline.	0.30
10/06/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	0.70
10/06/20	KM	Transition planning and team management re: project Catalyst.	0.90
10/06/20	GJK	Review potential upside COGS and related drivers for Mundipharma.	1.50
10/06/20	GJK	Review potential opex drivers for Mundipharma business plan upside.	2.00
10/06/20	GJK	Review market G&A potential re: Princen value accelerator outline.	2.00
10/06/20	GJK	Review potential revenue upside drivers for Mundipharma business plan.	2.00
10/06/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to debrief on current case status.	0.70
10/06/20	NAS	Review existing Mundipharma G&A product allocation methodology.	2.60
10/06/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma market clustering.	0.40
10/06/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to debrief on current case status.	0.70
10/06/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma market clustering.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/06/20	NAS	Develop potential upside scenarios for Mundipharma.	1.50
10/07/20	NAS	Review discovery motion filed by UCC and NCSG to identify implications for Mundipharma diligence.	0.90
10/07/20	NAS	Diligence call with L. Princen (Mundipharma), S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	0.80
10/07/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with L. McCracken (Mundipharma) and S. Jamieson (Management Revisions).	0.40
10/07/20	NAS	Develop potential upside scenarios for Mundipharma.	1.30
10/07/20	NAS	Document takeaways and action items following recent Mundipharma diligence calls with Purdue management.	0.60
10/07/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review potential upside performance opportunities for Mundipharma.	1.80
10/07/20	LJD	Review August monthly fee application	0.60
10/07/20	LJD	Review correspondence from UCC professionals	0.50
10/07/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with L. McCracken (Mundipharma) and S. Jamieson (Management Revisions).	0.40
10/07/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review potential upside performance opportunities for Mundipharma.	1.80
10/07/20	GJK	Diligence call with L. Princen (Mundipharma), S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	0.80
10/07/20	GJK	Plan and coordinate report updates relative to upside review.	1.50
10/07/20	GJK	Follow up from L. McCracken (Mundipharma) call relative	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to working capital management.	
10/07/20	KM	Develop Transition dashboard re: critical categories for integrated Smartsheet setup.	0.80
10/07/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	1.20
10/07/20	KM	Analysis re: tech transfers and volume requirements for Catalyst.	2.20
10/07/20	KM	Develop Transition dashboard re: Catalyst transition.	0.40
10/07/20	KM	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: smartsheet insights.	0.50
10/07/20	KM	Update workstream milestones re: project Catalyst quality activities.	0.50
10/07/20	KM	Update workstream milestones re: project Catalyst tech transfers.	0.30
10/07/20	KM	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst integration update.	1.10
10/07/20	KM	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition -Bill Grubb introduction.	
10/07/20	JD	Review list of material agreements from J. Lowne (Purdue).	0.30
10/07/20	JD	Prepare analysis of insider bonus payment amounts and correspondence with Willis Towers Watson and Davis Polk.	2.20
10/07/20	JD	Prepare actual professional fee tracker in order to share with Purdue management.	0.60
10/07/20	JD	Correspondence with Purdue management re: distributable value presentation.	0.30
10/07/20	JD	Create employee roster file to share with Skadden and King & Spalding.	2.50
10/07/20	JD	Review correspondence from Davis Polk re: KEIP/KERP discussions with Willis Towers Watson. Review WTW materials.	0.80
10/07/20	JD	Review correspondence from J. Lowne (Purdue) re: business performance summary to date.	0.50
10/07/20	JD	Call with J. Turner (PJT) re: diligence requests.	0.20
10/07/20	JD	Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review.	0.40
10/07/20	JD	Review the latest company roster and update the KEIP and KERP tracker. Correspondence with HR outlining any differences.	1.50
10/07/20	JD	Correspondence with Davis Polk and management re: overdue Cigna invoices and payment timing process.	0.40
10/07/20	ADD	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, A. Soma,	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst integration update.	
10/07/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	1.20
10/07/20	ADD	Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review.	0.40
10/07/20	ADD	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: smartsheet insights.	0.50
10/07/20	ADD	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, T. Deletant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition -Bill Grubb introduction.	0.60
10/08/20	ADD	Meeting with E. Ruta, J. Doyle (Purdue), K. McCarthy (Purdue), A. Gallogly (Skadden) and A. DePalma (AlixPartners) re: Catalyst contract reviews.	0.20
10/08/20	ADD	Meeting with V. Mancinelli, R. Shamblen, K. Kolar, A. Soma, D. McGuire, J. Northington, J. Fox, B. Evans J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - workstream interdependencies.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/08/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst status update.	0.60
10/08/20	ADD	Meeting with R. Shamblen, S. Aschmann, S. Yates, D. McGuire, J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst integration - Quality.	1.10
10/08/20	JD	Review draft presentation and analysis re: managed care customer.	0.60
10/08/20	JD	Provide estimates for professional fee accruals.	0.30
10/08/20	JD	Correspondence with Cigna and management re: invoice payment timing.	0.50
10/08/20	JD	Update KEIP/KERP attestation list for D. Warren (Purdue).	0.80
10/08/20	JD	Correspondence with Davis Polk re: potential KEIP/KERP declaration.	0.50
10/08/20	JD	Conversation with R. Aleali (Purdue) re: material contracts.	0.50
10/08/20	JD	Call with J. DelConte, K. McCafferty (both AlixPartners) and D. Lundie (Purdue) re: transition planning.	0.50
10/08/20	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: Rhodes transition planning.	0.30
10/08/20	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: Rhodes transition planning.	0.30
10/08/20	KM	Analysis re: Catalyst employee file update for circulation per J. Lowne (Purdue).	1.10
10/08/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.60
10/08/20	KM	Meeting with R. Shamblen, S. Aschmann, S. Yates, D. McGuire, J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/08/20	KM	AlixPartners) re: Catalyst integration - Quality. Meeting with V. Mancinelli, R. Shamblen, K. Kolar, A. Soma, D. McGuire, J. Northington, J. Fox, B. Evans J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - workstream interdependencies.	1.20
10/08/20	KM	Call with J. DelConte, K. McCafferty (both AlixPartners) and D. Lundie (Purdue) re: transition planning.	0.50
10/08/20	KM	Develop Transition dashboard re: Catalyst transition.	0.80
10/08/20	KM	Meeting with E. Ruta, J. Doyle (Purdue), K. McCarthy (Purdue), A. Gallogly (Skadden) and A. DePalma (AlixPartners) re: Catalyst contract reviews.	0.20
10/08/20	KM	Prepare updates re: catalyst Transition.	0.90
10/08/20	GJK	Plan and coordinate for report updates.	2.00
10/08/20	GJK	Review and edits to Appendix slides.	2.50
10/08/20	GJK	Review of previous Mundipharma reorganization per VDD.	2.00
10/08/20	JD	Correspondence with Davis Polk and management re: Side B due diligence requests.	0.70
10/08/20	JD	Review IMS data to be produced to creditors.	0.30
10/08/20	NAS	Review new diligence files and responses provided by Huron/Mundipharma.	1.00
10/08/20	NAS	Research rumored transaction for Mundipharma Israel JV (Rafa).	1.20
10/09/20	JD	Conversation with M. Florence (Skadden) and R. Aleali (Purdue) re: roster of employees.	0.50
10/09/20	JD	Call with J. Turner (PJT), B. Bromberg, M. Diaz (both FTI) and G. Coutts (Houlihan) re: BTCP Pharma discussions.	0.40
10/09/20	JD	Review diligence materials provided to Province re: cash	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		distribution report.	
10/09/20	JD	Update roster provided to Skadden in order to incorporate Executive Committee member and next level report details.	3.50
10/09/20	JD	Review Adhansia forecast build out file to provide to the creditor's advisors.	0.40
10/09/20	JD	Review models for other branded opioid forecasts.	0.40
10/09/20	GJK	Prepare for Deutsch Bank call to discuss status of Mundipharma transaction.	2.00
10/09/20	GJK	Review of updates needed based on new CEO.	1.50
10/09/20	GJK	Prepare workplan to finalize IAC diligence report.	2.00
10/09/20	GJK	Review of previous Mundipharma reorganization.	1.50
10/09/20	KM	Call with J. Giordano (Purdue) re: Catalyst transition.	0.30
10/09/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	0.50
10/09/20	KM	Project planning and management re: project Catalyst transition.	0.70
10/09/20	JD	Call with C. DeStefano (Purdue) re: retention payments.	0.50
10/09/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	0.50
10/12/20	ADD	Working sessions with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning.	2.20
10/12/20	ADD	Meeting with J. Giordano and Rhodes transition team (Purdue), A. DePalma, and K. McCafferty (both	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/12/20	ADD	AlixPartners) re: Project Catalyst Transition / Team Meeting: Noramco Qualifications and Tech Transfers. Call with A. DePalma, and K. McCafferty (both AlixPartners), A. Nadeau (Purdue) re: RT Contracts Review.	0.50
10/12/20	KM	Analysis re: Rhodes Pharma forecast sales.	1.70
10/12/20	KM	Call with A. DePalma, and K. McCafferty (both AlixPartners), A. Nadeau (Purdue) re: RT Contracts Review.	0.50
10/12/20	KM	Project planning and management re: project Catalyst transition.	0.50
10/12/20	KM	Analysis and preparation re: transition documentation for Noramco visit.	1.50
10/12/20	KM	Setup Smartsheet dashboard re: project Catalyst.	0.90
10/12/20	KM	Working sessions with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning.	2.20
10/12/20	KM	Meeting with J. Giordano and Rhodes transition team (Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Project Catalyst Transition / Team Meeting: Noramco Qualifications and Tech Transfers.	1.10
10/12/20	KM	Meeting with R. Shamblen, J. Waltz, A. Soma, A. Nadeau, J. Gibbs, B. Evans, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: SIOP 2021 forecast discussion in preparation for Noramco visit.	0.80
10/12/20	ADD	Meeting with R. Shamblen, J. Waltz, A. Soma, A. Nadeau, J. Gibbs, B. Evans, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: SIOP 2021 forecast discussion in preparation for Noramco visit.	0.80
10/12/20	GJK	Discussions with G. Koch, N. Simon (both AlixPartners)	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: next steps from Deutsche Bank Mundipharma sale process status update.	
10/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), Deutsche Bank, and other Mundipharma diligence advisors re: current status of sale process.	1.00
10/12/20	GJK	Discuss Mundipharma diligence with G. Koch, N. Simon (both AlixPartners) including DB call and net proceeds improvement ideas.	0.80
10/12/20	GJK	Call with I. McClatchey (Norton Rose) to discuss DB update.	0.50
10/12/20	GJK	Follow up on DB call including implications for business plan values.	2.70
10/12/20	GJK	Plan and coordinate Mundipharma diligence and report updates.	2.50
10/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, and I. Mian (all PJT) re: next steps following Deutsche Bank Mundipharma sales process update.	0.40
10/12/20	JD	Review forecasted professional fees for the remainder of the year from Purdue management in comparison to latest version of the AlixPartners forecast.	0.40
10/12/20	JD	Call with M. Huebner (Davis Polk) re: KEIP/KERP response.	0.20
10/12/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman (Purdue), J. O'Connell and J. Turner (both PJT) re: BTCP Pharma.	0.50
10/12/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC catch up.	0.30
10/12/20	JD	Review analyses prepared last year in response to open questions from the committees on the wage motion bonus payments.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/12/20	JD	Prepare summary of material contract review from Purdue to send along to Davis Polk for their contract review workstream.	0.40
10/12/20	JD	Prepare summary of CFO annualized retention to share with Willis Towers Watson and Davis Polk for their review.	0.50
10/12/20	JD	Review August business plan refresh numbers and OxyContin LOE assumptions at Purdue and at Rhodes. Correspondence with PJT and Purdue re: same.	1.20
10/12/20	JD	Review and provide comments on the draft PBC/DOJ deck for discussion with the AHC.	0.70
10/12/20	JD	Call with J. Lowne (Purdue) re: accounting close.	0.30
10/12/20	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP proposals and summaries.	0.50
10/12/20	JD	Call with J. Gartrell, S. Hinden, D. Sims (all Willis Towers Watson) re: KEIP metrics.	0.60
10/12/20	JD	Review updated annualized retention figures for Purdue insiders and associated analyses in WTW analysis.	1.10
10/12/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC catch up.	0.30
10/12/20	NAS	Discuss Mundipharma diligence with G. Koch, N. Simon (both AlixPartners) including DB call and net proceeds improvement ideas.	0.80
10/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, and I. Mian (all PJT) re: next steps following Deutsche Bank Mundipharma sales process update.	0.40
10/12/20	NAS	Prepare for call with Deutsche Bank on current status of Mundipharma sale process.	0.50
10/12/20	NAS	Discussions with G. Koch, N. Simon (both AlixPartners) re: next steps from Deutsche Bank Mundipharma sale	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		process status update.	
10/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), Deutsche Bank, and other Mundipharma diligence advisors re: current status of sale process.	1.00
10/12/20	NAS	Update Key Findings section of draft Mundipharma diligence report.	1.30
10/13/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), C. Robertson (DPW), J. Turner, J. Arsic, I. Mian (all PJT) to provide update on Mundipharma diligence process.	0.30
10/13/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) re: current state of Mundipharma diligence process and next steps.	0.80
10/13/20	NAS	Update Key Findings re: LAM overview slides in draft Mundipharma diligence report.	2.10
10/13/20	NAS	Update Key Findings re: China overview slides in draft Mundipharma diligence report.	1.10
10/13/20	NAS	Update Key Findings re: LAM Analgesics slides in draft Mundipharma diligence report.	2.70
10/13/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC updates.	0.20
10/13/20	GJK	Call with J. DelConte, G. Koch, N. Simon (all AlixPartners), J. Turner, J. Arsic (both PJT), C. Robertson and C. Oluwole (both Davis Polk) re: IAC discussions.	0.30
10/13/20	NAS	Call with J. DelConte, G. Koch, N. Simon (all AlixPartners), J. Turner, J. Arsic (both PJT), C. Robertson and C. Oluwole (both Davis Polk) re: IAC discussions.	0.30
10/13/20	JD	Review and provide comments on draft August flash report to provide to creditor advisors.	0.80
10/13/20	JD	Review materials from BTCP Pharma prior to scheduled	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		call.	
10/13/20	JD	Review correspondence from Dechert and Davis Polk re: DOJ deck.	0.30
10/13/20	JD	Call with J. Gartrell, D. Sims, S. Hinden (all Willis Towers Watson) and D. Consla (Davis Polk) re: KEIP/KERP.	0.70
10/13/20	JD	Prepare updated professional fee forecast after talking with Davis Polk for Debtor brief.	0.80
10/13/20	JD	Prepare summary of UCC KEIP proposal to share with Davis Polk, Willis Towers Watson and management.	1.70
10/13/20	JD	Call with J. DelConte, G. Koch, N. Simon (all AlixPartners), J. Turner, J. Arsic (both PJT), C. Robertson and C. Oluwole (both Davis Polk) re: IAC discussions.	0.30
10/13/20	JD	Call with committee members from the Ad Hoc Committee, Kramer Levin, Gilbert, Otterbourg, Davis Polk, Purdue and PJT re: post-emergence governance structure.	1.60
10/13/20	JD	Call with M. Huebner (Davis Polk) re: KEIP/KERP.	0.20
10/13/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC updates.	0.20
10/13/20	JD	Call with C. Robertson (Davis Polk) re: professional fee forecast.	0.40
10/13/20	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP.	0.30
10/13/20	GJK	Review Mundipharma business plan based on DB call.	2.50
10/13/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), C. Robertson (DPW), J. Turner, J. Arsic, I. Mian (all PJT) to provide update on Mundipharma diligence process.	0.30
10/13/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) re: current state of Mundipharma diligence process and next steps.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/13/20	GJK	Review investigation reports to prep for net proceeds improvement discussions.	3.00
10/13/20	KM	Develop reporting analyses and dashboard re: Catalyst Supply Chain workstream.	1.00
10/13/20	KM	Develop reporting analyses and dashboard re: Catalyst RT Operations workstream.	1.70
10/13/20	KM	Working sessions with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning.	2.00
10/13/20	KM	Meeting tracking and reporting re: project Catalyst transition site visit.	1.00
10/13/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola, V. Mancinelli, J. Gibbs, J. Giordano, D. McGuire, B. Evans, J. Fox (all Purdue) A. Gallogly, M. Gibson (Skadden) re: B. Grubb Coventry Site Visit: SIOP, 2021 Planning w/ Budget, Other 2021 Business Plan Considerations.	3.50
10/13/20	KM	Project planning and management re: project Catalyst transition.	1.30
10/13/20	KM	Develop reporting analyses and dashboard re: Catalyst Quality workstream.	1.50
10/13/20	KM	Draft presentation re: catalyst SteerCo meeting deck.	1.30
10/13/20	KM	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, J. Lowne (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) and Skadden legal team. re: Revised Closing Checklist.	0.40
10/13/20	KM	Update milestone tracking re: Catalyst quality workstream.	0.10
10/13/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Giordano (Purdue) re: Smartsheet IMO	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Assistance	
10/13/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, L. Rider, J. Giordano (all Purdue), B. Grubb (Noramco) and A. DePalma, K. McCafferty (both AlixPartners) re: B. Grubb Coventry Site Visit: Dronabinol Transfer, Buprenorphine Plans.	1.00
10/13/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, L. Rider, J. Giordano (all Purdue), B. Grubb (Noramco) and A. DePalma, K. McCafferty (both AlixPartners) re: B. Grubb Coventry Site Visit: Dronabinol Transfer, Buprenorphine Plans.	1.00
10/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Giordano (Purdue) re: Smartsheet IMO Assistance	0.90
10/13/20	ADD	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, J. Lowne (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) and Skadden legal team. re: Revised Closing Checklist.	0.40
10/13/20	ADD	Working sessions with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning.	2.00
10/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) J. Giordano (Purdue) re: project steering committee meeting readiness	1.00
10/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst status update.	0.20
10/14/20	KM	Approach re: Catalyst external document sharing.	0.60
10/14/20	KM	Prepare documents re: Catalyst SteerCo - Tech transfers update.	1.20
10/14/20	KM	Call with A. DePalma and K. McCafferty (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) J. Giordano (Purdue) re: project steering committee meeting readiness	
10/14/20	KM	Develop reporting analyses and dashboard re: Catalyst Supply Chain workstream.	1.90
10/14/20	KM	Prepare documents re: Catalyst SteerCo - Supply Chain update.	1.30
10/14/20	KM	Prepare documents re: Catalyst SteerCo - Finance update.	0.70
10/14/20	KM	Prepare documents re: Catalyst SteerCo - Quality update.	1.60
10/14/20	KM	Prepare documents re: Catalyst SteerCo - RT Operations update.	1.20
10/14/20	KM	Call with D. Fogel (Purdue) re: finance workstream review for SteerCo meeting.	0.60
10/14/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst status update.	0.20
10/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz and B. Bromberg (both FTI) re: current status of Mundipharma diligence process.	0.50
10/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma tax inquiry and follow-ups from call with FTI.	0.80
10/14/20	GJK	Prepare for FTI call and follow up notes.	1.00
10/14/20	GJK	Draft Mundipharma slide updates.	2.00
10/14/20	GJK	Plan and coordinate Mundipharma diligence including plans for advisor calls.	2.50
10/14/20	JD	Prepare detailed KEIP analyses taking into account creditor advisor proposal and potential company counterproposal. Correspondence with Davis Polk and Willis Towers Watson re: same.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/14/20	JD	Update HR tracking file for latest employee roster including updated salary and pay scale group. Correspondence with Purdue management re: same.	1.50
10/14/20	JD	Correspondence with Purdue management re: latest KEIP proposal.	0.30
10/14/20	JD	Review list of contract counterparties from Davis Polk and compare against list of essential contracts.	0.40
10/14/20	JD	Correspondence with Davis Polk and management re: material contract follow up questions from Davis Polk.	0.30
10/14/20	JD	Review and update latest professional fee forecast. Correspondence with Davis Polk re: using pro fee forecasts in the 2004 Discovery response briefs.	0.80
10/14/20	JD	Review summary correspondence from Davis Polk and management re: IAC sale process.	0.20
10/14/20	JD	Review final financial forecast presentation from PJT.	0.30
10/14/20	JD	Review list of missing contracts from Davis Polk against previous contract listings to try to identify where they are located.	0.40
10/14/20	JD	Call with R. Aleali (Purdue) re: contract review.	0.20
10/14/20	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP.	0.20
10/14/20	JD	Call with M. Huebner (Davis Polk) re: KEIP/KERP.	0.40
10/14/20	NAS	Update Key Findings re: Europe and Canada analgesics slides in draft Mundipharma diligence report.	1.10
10/14/20	NAS	Draft update for DPW and PJT re: status of Mundipharma diligence process.	0.40
10/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma tax inquiry and follow-ups from call with FTI.	0.80
10/14/20	NAS	Update Key Findings re: China overview slides in draft	3.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence report.	
10/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz and B. Bromberg (both FTI) re: current status of Mundipharma diligence process.	0.50
10/14/20	NAS	Review follow-up items and draft update for debtor advisors (DPW, PJT) post-Mundipharma discussion with FTI.	0.60
10/15/20	NAS	Update Key Findings re: Europe and Canada Analgesics slides in draft Mundipharma diligence report.	2.90
10/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), LEK, and other Mundipharma diligence advisors to review Commercial Due Diligence report.	1.10
10/15/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with LEK and prepare for update call with DPW.	0.60
10/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) and C. Robertson (DPW) to coordinate on next steps in Mundipharma diligence process.	0.40
10/15/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides in draft Mundipharma diligence report.	0.70
10/15/20	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP.	0.20
10/15/20	JD	Call with J. Gartrell, S. Hinden, D. Sims (all Willis Towers Watson), M. Huebner, J. McClammy, D. Consla (all Davis Polk) re: KEIP/KERP response.	0.80
10/15/20	JD	Correspondence with S. Lemack (AlixPartners) re: claims call with J. Lowne (Purdue).	0.30
10/15/20	JD	Review information sharing protocol re: states claim calculations.	0.30
10/15/20	JD	Review updated diligence questions re: Project Catalyst.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/15/20	JD	Review latest version of savings file.	0.70
10/15/20	JD	Catch up with R. Aleali (Purdue) re: post-management update call review and next steps.	0.30
10/15/20	GJK	Call with J. Turner (PJT), J. Ducharme, R. Fanelli, M. Kwarcinski, S. Daniel, C. George (all Purdue) re: REMS discussions.	0.20
10/15/20	GJK	Call with A. DePalma and G. Koch (both AlixPartners) re: States' confidential claim information sharing protocol.	2.50
10/15/20	GJK	Update Mundipharma diligence slides.	2.50
10/15/20	GJK	Develop 2020 update materials for Mundipharma diligence report.	0.60
10/15/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with LEK and prepare for update call with DPW.	0.40
10/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) and C. Robertson (DPW) to coordinate on next steps in Mundipharma diligence process.	1.10
10/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), LEK, and other Mundipharma diligence advisors to review Commercial Due Diligence report.	1.00
10/15/20	KM	Follow up on Information Sharing Protocol including review of documents, email exchanges.	0.50
10/15/20	KM	Call with K. McCarthy and J. Giordano (Purdue) re: process for sharing external documents.	1.50
10/15/20	KM	Integrate cross-functional milestones re: project Catalyst.	0.80
10/15/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts workstream discussion	0.70
10/15/20	KM	Call with S. Yates (Purdue) re: Catalyst transition Quality	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		function in Coventry.	
10/15/20	KM	Update Transition dashboard re: project Catalyst.	1.60
10/15/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) J. Doyle and E. Ruta (both Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.40
10/15/20	KM	Develop reporting analyses and dashboard re: Catalyst Quality workstream.	0.80
10/15/20	ADD	Call with A. DePalma and G. Koch (both AlixPartners) re: States' confidential claim information sharing protocol.	0.20
10/15/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) J. Doyle and E. Ruta (both Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.40
10/15/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts workstream discussion	0.80
10/16/20	KM	Analysis and revisions re: project Catalyst savings.	0.90
10/16/20	KM	Call with J. Giordano (Purdue) re: Catalyst SteerCo follow up and next steps.	0.50
10/16/20	KM	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, K. Kolar, A. Soma, J. Doyle (Purdue), J. Lowne, D. McGuire, J. Northington, B. Evans, J. Giordano (Purdue), and K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst Steering Committee meeting.	1.50
10/16/20	KM	Develop Transition dashboard re: project Catalyst Tech Transfers.	0.80
10/16/20	ADD	Meeting with D. Lundie, V. Mancinelli, R. Shamblen, K. Kolar, A. Soma, J. Doyle (Purdue), J. Lowne, D. McGuire, J. Northington, B. Evans, J. Giordano (Purdue), and K.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, A. DePalma (both AlixPartners) re: Catalyst Steering Committee meeting.	
10/16/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from discussions with other Mundipharma diligence advisors.	0.30
10/16/20	GJK	Create slides for Mundipharma diligence report.	1.70
10/16/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: KEIP/KERP.	0.30
10/16/20	GJK	Plan and coordinate Mundipharma diligence.	1.50
10/16/20	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP.	0.10
10/16/20	JD	Prepare correspondence to send around updated KEIP analysis to other members of Purdue management.	0.80
10/16/20	JD	Prepare summary KEIP analysis per request from J. Lowne (Purdue).	0.40
10/16/20	JD	Call with M. Kesselman (Purdue) re: KEIP/KERP.	0.10
10/16/20	JD	Call with M. Huebner (Davis Polk) re: KEIP/KERP.	0.20
10/16/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: KEIP/KERP.	0.30
10/16/20	JD	Update latest analysis and correspondence with Purdue management re: shift and OT premium calculations.	0.70
10/16/20	JD	Update KEIP analysis summary for comments from Davis Polk.	0.60
10/16/20	JD	Update KEIP analysis to include the amounts for the CFO in addition to the 4 other insiders.	1.50
10/16/20	JD	Follow up with Davis Polk re: Project Catalyst savings analysis.	0.40
10/16/20	JD	Update and finalize professional fee forecast analysis to be shared with the company for preliminary 2021 forecast	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and 2020 annual update.	
10/16/20	JD	Correspondence with Purdue management re: REMS discussion summary memo.	0.30
10/16/20	JD	Correspondence with Purdue management re: OT and premium annualization calculations.	0.30
10/16/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from discussions with other Mundipharma diligence advisors.	0.30
10/16/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for biosimilars in draft Mundipharma diligence report.	2.20
10/16/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for diabetes in draft Mundipharma diligence report.	0.90
10/17/20	JD	Call with M. Kesselman, K. Laurel (both Purdue), D. Consla (Davis Polk) re: KEIP/KERP.	0.40
10/17/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP.	0.20
10/17/20	JD	Correspondence with Davis Polk and management re: KEIP/KERP response.	0.90
10/18/20	GJK	Review 2020 Mundipharma updates provided by management.	2.00
10/19/20	GJK	Edit 2020 update slides for Mundipharma report.	2.00
10/19/20	GJK	Edit 2020 update slides for Mundipharma report, including review of Q1 and 1H results.	3.00
10/19/20	GJK	Create 2020 update slides for Mundipharma report.	3.00
10/19/20	JD	Prepare 2 potential KEIP counterproposals to send around to the group for comments.	1.50
10/19/20	JD	Correspondence with Purdue management re: UST payments.	0.20
10/19/20	JD	Update analysis to include final counterproposal.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/19/20	JD	Correspondence with Davis Polk and management re: KEIP analyses and proposal and counterproposal overviews.	0.90
10/19/20	JD	Participate in PPI Board meeting with L. Donahue, J. DelConte (both AlixPartners), management and board members.	1.80
10/19/20	JD	Call with M. Huebner (Davis Polk) re: KEIP/KERP analysis.	0.50
10/19/20	JD	Review updated UCC KEIP proposal and prepare updated KEIP analysis.	1.60
10/19/20	JD	Prepare updated analysis of P50 and P75 WTW comp survey ranges in relation to latest UCC proposal.	0.80
10/19/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for Diabetes in draft Mundipharma diligence report.	0.80
10/19/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for Respiratory in draft Mundipharma diligence report.	1.50
10/19/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for Oncology in draft Mundipharma diligence report.	1.00
10/19/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for Other Ethical in draft Mundipharma diligence report.	2.20
10/19/20	NAS	Update Key Findings re: Non-Analgesic portfolio slides for Consumer Health in draft Mundipharma diligence report.	1.30
10/19/20	NAS	Update Key Findings re: major cost line items in draft Mundipharma diligence report.	1.30
10/19/20	LJD	Participate in PPI Board meeting with L. Donahue, J. DelConte (both AlixPartners), management and board members.	1.80
10/19/20	KM	Transition plan update re: tech transfers.	1.80
10/19/20	KM	Reporting analyses and dashboard re: Catalyst Rhodes Pharma Tech Transfers workstream.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/19/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Eber, J. Waltz, B. Mayer, K. Kolar, E. Michelson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue) re: Catalyst transition - Noramco qualifications and Tech transfers.	1.00
10/19/20	KM	Update transition tracking and milestones re: project Catalyst.	2.20
10/19/20	KM	Project planning and management re: project Catalyst transition.	1.80
10/20/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Waltz (Purdue) re: tech transfer timeline.	1.20
10/20/20	KM	Update workplan re: RT tech transfers.	0.50
10/20/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), E. Ruta, J. Doyle, D. Fogel, P. Brinckerhoff, K. McCarthy (all Purdue) re: Catalyst transition - tech contracts.	1.00
10/20/20	KM	Analysis and project management re: Catalyst transition.	0.80
10/20/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst contracts tracking.	1.10
10/20/20	KM	Meeting with S. Yates, S. Ashmann (Purdue), J. Northington, D. Eades, B. Purdon, J. Giordano (Purdue) and A. DePalma (AlixPartners) re: Catalyst transition - Quality.	1.10
10/20/20	KM	Review progress and update tracking re: meeting prep Catalyst transition - quality.	1.00
10/20/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano and Rhodes Supply Chain transition team (all Purdue) re: Catalyst transition - Supply Chain.	1.00
10/20/20	KM	Review progress and update tracking re: meeting prep Catalyst transition - Supply Chain.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/20/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), A. Nadeau, A. Soma, J. Giordano (all Purdue) re: Catalyst transition - RT operations.	1.00
10/20/20	KM	Review progress and update tracking re: meeting prep Catalyst transition - RT Ops.	0.80
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst contracts workstream discussion	1.10
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), A. Nadeau, A. Soma, J. Giordano (all Purdue) re: Catalyst transition - RT operations.	1.00
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano and Rhodes Supply Chain transition team (all Purdue) re: Catalyst transition - Supply Chain.	1.00
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano and Rhodes Quality transition team (all Purdue) re: Catalyst transition - Quality.	1.10
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), E. Ruta, J. Doyle, D. Fogel, P. Brinckerhoff, K. McCarthy (all Purdue) re: Catalyst transition - tech contracts.	1.00
10/20/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Waltz (Purdue) re: tech transfer timeline.	1.20
10/20/20	NAS	Review new Mundipharma diligence slides provided by G. Koch (AlixPartners).	0.50
10/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma diligence report.	1.00
10/20/20	NAS	Add Product Contribution metric to Mundipharma model and corresponding tables to draft diligence report.	3.10
10/20/20	JD	Correspondence with Purdue and with Cigna re: invoice payment timing.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/20/20	JD	Correspondence with C. DeStefano and D. Warren (both Purdue) re: KERP individual calculations.	0.50
10/20/20	JD	Call with J. Lowne (Purdue) re: business plan process and KEIP negotiations.	0.50
10/20/20	JD	Prepare updated KEIP proposal response to send around to the various creditor constituencies.	1.20
10/20/20	JD	Correspondence with Purdue management re: update on KEIP negotiations.	0.40
10/20/20	JD	Prepare analysis of annualized OT and premium amounts for KERP calculations.	2.00
10/20/20	JD	Incorporate updates to the latest KERP calculations and share with C. DeStefano and D. Warren (both Purdue).	2.40
10/20/20	GJK	Walkthrough and prepare discussion points for latest Mundipharma report draft.	2.00
10/20/20	GJK	Assess potential upside/downside risks of potential business plan revisions.	3.00
10/20/20	GJK	Update and edit Mundipharma report slides.	1.00
10/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma diligence report.	1.00
10/21/20	GJK	Edit diligence slides for Mundipharma report.	3.00
10/21/20	GJK	Update and edit diligence slides for Mundipharma report.	3.00
10/21/20	GJK	Plan and coordinate Mundipharma diligence for report planning purposes.	2.00
10/21/20	JD	Correspondence with Purdue, Teneo and Davis Polk re: media questions post DOJ press conference.	0.70
10/21/20	JD	Correspondence with Davis Polk and Purdue re: KEIP proposal.	0.40
10/21/20	JD	Prepare summary KEIP analysis for internal discussions.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/21/20	JD	Review and provide comments to a preliminary draft KEIP declaration.	1.50
10/21/20	JD	Review and prepare analysis of previous retention payment summaries.	1.30
10/21/20	JD	Prepare initial analysis of potential retention program. Compare against historical payment amounts and prepare summary for C. DeStefano (Purdue).	2.10
10/21/20	JD	Review list of AlixPartners personnel for Purdue system access.	0.20
10/21/20	JD	Review Fidelity analysis re: PBGC distressed termination claim.	0.30
10/21/20	JD	Review draft WTW supplemental declaration.	0.40
10/21/20	JD	Call with D. Consla (Davis Polk) re: KEIP negotiations.	0.20
10/21/20	NAS	Build standalone region P&Ls in Mundipharma business plan model.	2.40
10/21/20	NAS	Add standalone region P&L tables to draft Mundipharma diligence report.	1.00
10/21/20	NAS	Review revisions to Key Findings section of draft Mundipharma diligence report.	0.50
10/21/20	NAS	Draft net working capital slides for Mundipharma diligence report.	1.80
10/21/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano and Rhodes transition team (Purdue) re: Project Catalyst Transition / Team Meeting: Noramco Qualifications and Tech Transfers - smartsheet training	0.90
10/21/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transitions work planning	1.90
10/21/20	ADD	Research and compile agreement requested by Davis Polk	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for review.	
10/21/20	ADD	Meeting with J. Waltz, D. Eber (Purdue), J. Fox, D. Eades, W. Addicks (Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: tech transfer completion.	0.50
10/21/20	KM	Analysis re: tech transfers timing for Catalyst.	0.80
10/21/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Giordano and Rhodes transition team (Purdue) re: Project Catalyst Transition / Team Meeting: Noramco Qualifications and Tech Transfers - smartsheet training	0.90
10/21/20	KM	Meeting with J. Waltz, D. Eber (Purdue), J. Fox, D. Eades, W. Addicks (Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: tech transfer completion.	0.50
10/21/20	KM	Call with D. Fogel (Purdue) and J. Giordano (Purdue) re: Catalyst finance update.	0.80
10/21/20	KM	Analysis re: IT and services contracts.	0.90
10/21/20	KM	Analysis re: laboratory contracts.	1.70
10/21/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transitions work planning	1.90
10/21/20	KM	Project planning and management re: project Catalyst transition.	1.70
10/22/20	KM	Build milestone tracker by drug product re: Rhodes Pharma tech transfers.	2.30
10/22/20	KM	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: Smartsheet IMO Assistance	0.70
10/22/20	KM	Tracking and reporting re: Catalyst tech transfers.	1.00
10/22/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/22/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.50
10/22/20	KM	Call with D. Fogel and W. DiNicola (Purdue) re: finance transition planning.	1.00
10/22/20	KM	Update milestone and workplan re: project Catalyst - Finance.	0.70
10/22/20	KM	Meeting with J. Waltz, D. Eades, B. Evans, J. fox, J. Giordano (all Purdue) re: tech transfer planning for Catalyst.	0.90
10/22/20	KM	Update milestone and workplan re: project Catalyst - Supply Chain.	0.70
10/22/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst contracts workstream status discussion.	0.70
10/22/20	KM	Project planning and management re: project Catalyst transition.	1.10
10/22/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.40
10/22/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst contracts workstream status discussion	0.70
10/22/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden) re: Catalyst - Continuing Contract Review.	0.50
10/22/20	NAS	Review updated diligence overview slides for draft Mundipharma diligence report.	0.90
10/22/20	NAS	Review of current draft of Mundipharma diligence report	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		with G. Koch, N. Simon (both AlixPartners).	
10/22/20	NAS	Implement global revisions to latest draft of Mundipharma diligence report.	1.00
10/22/20	NAS	Draft net working capital slides for Mundipharma diligence report.	0.70
10/22/20	NAS	Review comments to Key Findings section of draft Mundipharma diligence report and implement changes.	2.30
10/22/20	JD	Review correspondence from Purdue, Davis Polk and PJT re: media responses.	0.30
10/22/20	JD	Review updated draft KEIP supplemental declaration.	0.50
10/22/20	JD	Review intercompany matrix per creditor committee request.	0.30
10/22/20	JD	Review comments to the draft supplemental KEIP declaration. Edit and provide comments.	1.80
10/22/20	JD	Correspondence with PJT re: banking services.	0.20
10/22/20	JD	Call with J. Lowne (Purdue) re: R&D spending.	0.20
10/22/20	GJK	Review and edit key findings slides for Mundipharma report.	3.00
10/22/20	GJK	Review and edit risk adjustment slides for Mundipharma report.	2.00
10/22/20	GJK	Review of current draft of Mundipharma diligence report with G. Koch, N. Simon (both AlixPartners).	1.50
10/22/20	GJK	Review of latest draft of Mundipharma report.	2.00
10/23/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review current draft of Mundipharma diligence report.	1.10
10/23/20	GJK	Review update draft of Mundipharma report.	3.00
10/23/20	GJK	Comments and edits on updated Mundipharma report.	2.00
10/23/20	JD	Review checks to the KERP master file from C. DeStefano	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and D. Warren (both Purdue).	
10/23/20	JD	Correspondence with C. DeStefano and D. Warren (both Purdue) re: KERP calculations.	0.40
10/23/20	JD	Update KERP calculations using rounded percentage reductions and compare to existing KERP calculations.	1.30
10/23/20	JD	Update latest professional fee tracker and go-forward forecast.	0.30
10/23/20	JD	Provide exact KEIP reduction percentages to C. DeStefano (Purdue) for calculation checks.	0.20
10/23/20	JD	Provide summary KEIP tables for K. Laurel and M. Kesselman (both Purdue) for internal conversations.	0.40
10/23/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review current draft of Mundipharma diligence report.	1.10
10/23/20	NAS	Revise Executive Summary section of draft Mundipharma diligence report.	2.80
10/23/20	NAS	Brainstorm slides for Executive Summary of draft Mundipharma diligence report.	1.20
10/23/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition work planning.	0.50
10/23/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), A. Raina (Purdue) re: Project Catalyst Transition / Team Meeting: IT Smartsheet Discussion	0.80
10/23/20	ADD	Meeting with E. Ruta (Purdue) K. McCafferty, A. DePalma (both AlixPartners) re: RT contract list.	0.50
10/23/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition work planning.	0.50
10/23/20	KM	Upgrade IT dashboard re: Catalyst agreement tracking.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/23/20	KM	Analysis re: IT transition expense tracking.	0.60
10/23/20	KM	Meeting with E. Ruta (Purdue) K. McCafferty, A. DePalma (both AlixPartners) re: RT contract list.	0.50
10/23/20	KM	Call with D. Fogel (Purdue) and R. Schlossberg (Skadden) re: MSA pricing terms.	0.50
10/23/20	KM	Build reporting functionality re: Catalyst transition dashboard.	1.00
10/23/20	KM	Call with J. Giordano (Purdue) re: project Catalyst PMO update.	0.50
10/23/20	KM	Project planning and management re: project Catalyst transition.	0.30
10/23/20	KM	Call with B. Grubb (Noramco) re: transition.	0.70
10/23/20	KM	Update dashboard and flash report re: Catalyst IT transition.	0.20
10/23/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), A. Raina (Purdue) re: Project Catalyst Transition / Team Meeting: IT Smartsheet Discussion	0.80
10/23/20	KM	Tracking and reporting re: Catalyst IT transition.	1.90
10/24/20	JD	Review supplemental KEIP statement and declaration.	0.50
10/25/20	JD	Correspondence with Davis Polk and Willis Towers Watson re: UCC KEIP diligence questions. Review materials re: same.	0.40
10/25/20	JD	Review updated draft KEIP order.	0.30
10/26/20	JD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence items.	0.40
10/26/20	JD	Correspondence with Davis Polk re: open KEIP/KERP issues	0.50
10/26/20	JD	Correspondence with Purdue re: KERP master files.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/26/20	JD	Review Willis Towers Watson analysis re: Province KERP questions.	0.50
10/26/20	JD	Review and provide comments on the narrative from Davis Polk re: supplemental KERP motion.	0.70
10/26/20	JD	Prepare analysis of CEO and CFO compensation in advance of KEIP negotiations.	2.70
10/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma diligence report.	1.00
10/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, M. Diaz, B. Bromberg (all FTI), S. Burian, G. Coutts (both HL) to share takeaways following diligence call with M. Princen (Mundipharma).	0.70
10/26/20	GJK	Walkthrough and edits to Mundipharma report slides.	2.50
10/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review analysis of M. Princen's (Mundipharma) strategy.	3.00
10/26/20	GJK	Diligence call with M. Princen (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	1.10
10/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from diligence meeting with M. Princen (Mundipharma).	0.40
10/26/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to share takeaways from diligence meeting with M. Princen (Mundipharma).	0.40
10/26/20	NAS	Revise 2020 Update section of draft Mundipharma diligence report.	1.10
10/26/20	NAS	Incorporate revisions from counsel (DPW) into draft Mundipharma diligence report.	1.90
10/26/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		latest draft of Mundipharma diligence report.	
10/26/20	NAS	Review and revise update notes from call with M. Princen (Mundipharma) for counsel (DPW).	0.30
10/26/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, M. Diaz, B. Bromberg (all FTI), S. Burian, G. Coutts (both HL) to share takeaways following diligence call with M. Princen (Mundipharma).	0.70
10/26/20	NAS	Revise Executive Summary section of draft Mundipharma diligence report.	1.50
10/26/20	NAS	Prepare for call with M. Princen (Mundipharma) RE: business plan.	0.20
10/26/20	NAS	Diligence call with M. Princen (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	1.10
10/26/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning status discussion.	1.10
10/26/20	KM	Meeting with S. Engel, J. Narliss (Purdue), P. Brinkerhoff, M. Gupta, N. Feldman, A. Raina (all Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: IT workstream update.	0.50
10/26/20	KM	Project planning and management re: project Catalyst transition.	0.80
10/26/20	KM	Build milestone tracker by drug product re: Purdue Pharma tech transfers.	1.00
10/26/20	KM	Analysis and tracker update re: Catalyst transition - RT tech transfers.	1.70
10/26/20	KM	Develop IT implementation expense tracking re: Catalyst transition.	0.90
10/26/20	KM	Call with D. Ebere (Purdue) re: BD and pipeline project	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management.	
10/26/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Eber, J. Waltz, B. Mayer, K. Kolar, E. Michelson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	0.90
10/26/20	KM	Update Flash reports re: project Catalyst.	1.30
10/26/20	ADD	Call A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst transition planning status discussion.	1.10
10/26/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Deletant, D. Eber, J. Waltz, B. Mayer, K. Kolar, E. Michelson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	0.90
10/26/20	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence items.	0.40
10/26/20	HSB	Review Purdue board deck for Pipeline updates ahead of call with management and external parties.	0.70
10/27/20	ADD	Virtual working session A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst transition planning.	1.20
10/27/20	ADD	Review accounting treatment for claims and liabilities subject to compromise.	1.50
10/27/20	ADD	Meeting with A. Nadeau, J. Waltz, J. Gibbs, B. Evans, J. Fox, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Supply Chain.	0.90
10/27/20	ADD	Meeting with S. Yates, S. Ashmann (Purdue), J. Northington, D. Eades, B. Purdon, J. Giordano (Purdue)	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	
10/27/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	0.30
10/27/20	ADD	Meeting with A. Soma, A. Nadeau, R. Shamblen (Purdue), J. Giordano (Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT operations	0.70
10/27/20	KM	Project planning and management re: project Catalyst transition.	1.10
10/27/20	KM	Analysis and tracker update re: Catalyst transition - Quality.	1.30
10/27/20	KM	Meeting with S. Yates, S. Ashmann (Purdue), J. Northington, D. Eades, B. Purdon, J. Giordano (Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	1.00
10/27/20	KM	Meeting with A. Soma, A. Nadeau, R. Shamblen (Purdue), J. Giordano (Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT operations	0.70
10/27/20	KM	Virtual working session A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst transition planning.	1.20
10/27/20	KM	Analysis and tracker update re: Catalyst transition - RT Operations.	1.30
10/27/20	KM	Analysis and tracker update re: Catalyst transition - Supply Chain.	1.50
10/27/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	0.30
10/27/20	KM	Meeting with A. Nadeau, J. Waltz, J. Gibbs, B. Evans, J. Fox, J. Giordano (all Purdue), K. McCafferty and A.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DePalma (both AlixPartners) re: Catalyst transition - Supply Chain.	
10/27/20	NAS	Review news related to Purdue Canada Quebec class action.	0.20
10/27/20	NAS	Review existing Appendix of draft Mundipharma diligence report for potential additions.	0.80
10/27/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss workstream priorities and latest case updates.	0.50
10/27/20	NAS	Follow up and coordinate on Mundipharma diligence following call with M. Princen (Mundipharma).	1.80
10/27/20	GJK	Plan and coordinate Mundipharma diligence.	2.00
10/27/20	GJK	Review possible performance drivers in a potential revised Mundipharma business plan.	3.00
10/27/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss workstream priorities and latest case updates.	0.50
10/28/20	GJK	Summarize conclusions from analysis of M. Princen (Mundipharma) strategy.	0.80
10/28/20	JD	Call with J. Lowne and C. DeStefano (both Purdue) re: incentive comp forecasting.	0.40
10/28/20	JD	Call with J. Lowne (Purdue) re: business plan.	0.20
10/28/20	JD	Finalize master KERP spreadsheet and send to D. Warren and C. DeStefano (both Purdue).	2.00
10/28/20	NAS	Model financial impact of strategies discussed by M. Princen (Mundipharma).	3.50
10/28/20	NAS	Draft request list for follow-up items after discussion with PJT FTI, HL.	0.80
10/28/20	NAS	Review Purdue documents released by House Oversight Committee.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/28/20	GJK	Review second phase diligence responses for potential Mundipharma Appendix updates.	3.00
10/28/20	GJK	Review FTEs in Mundipharma business for potential reductions.	1.00
10/28/20	KM	Project planning and management re: project Catalyst transition.	1.10
10/28/20	KM	Develop and build finance reporting structure re: project Catalyst.	2.30
10/28/20	KM	Analysis re. workstream interdependencies for Catalyst.	0.90
10/28/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	1.00
10/28/20	KM	Integrate SteerCo reporting functionality re: Catalyst transition dashboard.	1.90
10/28/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	1.00
10/28/20	ADD	Compile Purdue agreements requested by Davis Polk for review.	0.80
10/28/20	ADD	Prepare responses to Davis Polk's diligence questions for review by Purdue personnel leveraging information disclosed in the SOFAs and Schedules.	2.50
10/29/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	2.70
10/29/20	ADD	Continue virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts analysis.	0.80
10/29/20	ADD	Virtual working session A. DePalma and K. McCafferty	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both AlixPartners) re: Project Catalyst contracts analysis.	
10/29/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden), P. Brinckerhoff, K. McCarthy re: Catalyst - Continuing Contract Review.	1.20
10/29/20	ADD	Meeting with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (both Purdue) re: transformation tracking - Finance.	1.70
10/29/20	KM	Project planning and management re: project Catalyst transition.	1.30
10/29/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Doyle and E. Ruta (Purdue), A. Gallogly, C. Yuh (Skadden), P. Brinckerhoff, K. McCarthy re: Catalyst - Continuing Contract Review.	1.20
10/29/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contracts analysis.	2.70
10/29/20	KM	Analysis re: lab and IT contracts.	1.50
10/29/20	KM	Continue virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts analysis.	0.80
10/29/20	KM	Meeting with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (both Purdue) re: transformation tracking - Finance.	1.70
10/29/20	KM	Reporting and tracker update re: lab and IT contracts.	0.80
10/29/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts analysis.	0.50
10/29/20	GJK	Review potential headcount reduction mechanics for Mundipharma, including historical reductions and associated cash outlays.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/29/20	GJK	Review product line break even for low margin products identified by M Princen (Mundipharma).	2.00
10/29/20	GJK	Review country by country profitability for potential consolidation or change in go to market strategy for Mundipharma.	1.50
10/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review analysis of M. Princen's (Mundipharma) strategy.	0.70
10/29/20	NAS	Model financial impact of strategies discussed by M. Princen (Mundipharma).	0.60
10/29/20	NAS	Draft information request note to Mundipharma as follow up from call with M Princen (Mundipharma).	0.70
10/29/20	NAS	Revise Europe section of Mundipharma diligence report Appendix.	2.30
10/29/20	NAS	Revise LAM and Canada sections of Mundipharma diligence report Appendix.	2.00
10/29/20	NAS	Revise Overview section of Mundipharma diligence report Appendix.	0.80
10/29/20	LJD	Participate in Purdue Board meeting with L. Donahue, J. DelConte (both AlixPartners), Management and Board Members	2.90
10/29/20	JD	Participate in Purdue Board meeting with L. Donahue, J. DelConte (both AlixPartners), Management and Board Members	2.90
10/29/20	JD	Call with C. Robertson (Davis Polk) re: board meeting follow ups.	0.20
10/29/20	JD	Update KERP master tracking file per requests from C. DeStefano and D. Warren (both Purdue).	1.00
10/29/20	JD	Review and provide comments on latest PEO monthly flash report.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/29/20	JD	Review PJT vs. AHC distributable value comparison.	0.40
10/29/20	JD	Review contracts collected per Davis Polk request for trust transfer review.	1.50
10/30/20	JD	Prepare comparative analysis of UCC, AHC and Debtor legal fees.	0.40
10/30/20	JD	Review latest filed fee apps and update professional fee tracker and forecast.	0.80
10/30/20	JD	Begin preparation of LTRP and AIP forecast for updated long-term business plan.	2.60
10/30/20	JD	Begin preparing master LTRP tracking sheet for management to better track long term incentive compensation awards.	2.90
10/30/20	JD	Review and provide comments on initial draft PBC deck from Davis Polk.	0.50
10/30/20	JD	Review introductory brief per Province diligence request.	0.30
10/30/20	JD	Call with M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk) re: UCC diligence questions.	0.30
10/30/20	NAS	Update KPMG/tax slides in Appendix of draft Mundipharma diligence report.	1.50
10/30/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review Appendix to latest draft of Mundipharma diligence report.	0.40
10/30/20	NAS	Correspondence with other Mundipharma diligence advisors re: additional diligence requests.	0.20
10/30/20	NAS	Revise Appendix to draft Mundipharma diligence report.	1.40
10/30/20	NAS	Build overview of comparable Net Sales, Gross Margin, and EBITDA between iterations of Mundipharma forecasts for Appendix of diligence report.	2.10
10/30/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review Appendix to latest draft of Mundipharma diligence report.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/30/20	GJK	Follow up and coordinate on next steps for Mundipharma diligence including outreach to Advisors re: IAC taxes.	2.50
10/30/20	GJK	Review Mundipharma report for open items for potential new Appendix slides.	2.00
10/30/20	KM	Project planning and management re: project Catalyst transition.	1.00
10/30/20	KM	Meeting with D. Fogel, W. DiNicola, A. Soma, J. Giordano (all Purdue), and Bill Grubb (Noramco) re: 2021 budget preview.	1.30
10/30/20	KM	Meeting with J. Giordano (Purdue) re: Catalyst status update.	0.50
10/30/20	KM	Develop and build SteerCo flash reporting structure re: project Catalyst.	2.10
10/30/20	KM	Follow up with J. Waltz (Purdue) re: buprenorphine pricing.	0.40
10/30/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract question	0.20
10/30/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract question	0.20
10/30/20	ADD	Update schedule of leases with feedback from Purdue for Davis Polk's review.	1.10
10/30/20	ADD	Compile Purdue lease agreements requested by Davis Polk.	1.70
10/30/20	ADD	Compile Rhodes contracts requested by Davis Polk as part of a diligence review.	2.30
10/30/20	ADD	Draft correspondence requesting outstanding Rhodes agreements for Davis Polk review.	0.30
10/30/20	ADD	Review Rhodes Tech master contract list to update reconciliation to contract disclosure schedules.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
Total			655.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	75.90	515.00	39,088.50
Nate A Simon	114.80	515.00	59,122.00
Gabe J Koch	148.30	840.00	124,572.00
HS Bhattal	0.70	840.00	588.00
Jesse DelConte	127.30	950.00	120,935.00
Kevin M McCafferty	182.30	950.00	173,185.00
Lisa Donahue	5.80	1,195.00	6,931.00
Total Hours & Fees	655.10		524,421.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
10/01/20	ADD	Meeting with A. DePalma and S. Lemack (both AlixPartners) to discuss liquidation analysis and follow-up items.	0.40
10/01/20	SKL	Update liquidation analysis with latest LSTC trade info provided by A. DePalma (AlixPartners).	1.30
10/01/20	SKL	Update liquidation analysis with latest claims information provided by Prime Clerk team.	1.90
10/01/20	SKL	Update liquidation analysis with latest PBGC information and provided placeholder for future updates.	1.10
10/01/20	SKL	Finalize remaining updates to the liquidation analysis and circulate for additional feedback.	2.30
10/01/20	SKL	Meeting with A. DePalma and S. Lemack (both AlixPartners) to discuss liquidation analysis and follow-up items.	0.40
10/06/20	HSB	Review updated excel file with liquidation analysis prepared by S. Lemack (AlixPartners).	0.60
10/06/20	HSB	Continue to review updated excel file with liquidation analysis prepared by S. Lemack (AlixPartners).	0.60
10/07/20	HSB	Meeting with HS Bhattal (AlixPartners) and S. Lemack (AlixPartners) to discuss additional updates to be made to the liquidation analysis and cash forecast.	0.80
10/07/20	HSB	Review updated excel file with liquidation analysis prepared by S. Lemack (AlixPartners).	0.40
10/07/20	SKL	Meeting with HS Bhattal (AlixPartners) and S. Lemack (AlixPartners) to discuss additional updates to be made to the liquidation analysis and cash forecast.	0.80
10/08/20	SKL	Call with J. DelConte, K. McCafferty, S. Lemack (all AlixPartners) re: liquidation analysis.	0.50
10/08/20	SKL	Finalize remaining updates to the latest liquidation	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		analysis prior to this afternoon's meeting.	
10/08/20	SKL	Finalize remaining updates to the liquidation analysis following this afternoon's meeting.	1.70
10/08/20	SKL	Meeting with H. Bhattal, S. Lemack (both AlixPartners) to review latest updates made to the liquidation analysis and upcoming liquidation analysis meeting.	0.40
10/08/20	SKL	Meeting with J. Lowne (Purdue), J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss draft liquidation analysis and next steps.	0.80
10/08/20	SKL	Meeting with J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to discuss next steps re: liquidation analysis.	0.30
10/08/20	SKL	Meeting with J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to discuss liquidation analysis and upcoming call.	0.40
10/08/20	JD	Meeting with J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to discuss liquidation analysis and upcoming call.	0.40
10/08/20	HSB	Meeting with H. Bhattal, S. Lemack (both AlixPartners) to review latest updates made to the liquidation analysis and upcoming liquidation analysis meeting.	0.40
10/08/20	HSB	Meeting with J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to discuss liquidation analysis and upcoming call.	0.40
10/08/20	HSB	Meeting with J. Lowne (Purdue), J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss draft liquidation analysis and next steps.	0.80
10/08/20	HSB	Meeting with J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to discuss next steps re: liquidation analysis.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
10/08/20	ADD	Meeting with J. Lowne (Purdue), J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss draft liquidation analysis and next steps.	0.80
10/08/20	ADD	Meeting with J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to discuss next steps re: liquidation analysis.	0.30
10/08/20	KM	Call with J. DelConte, K. McCafferty, S. Lemack (all AlixPartners) re: liquidation analysis.	0.50
10/08/20	ADD	Meeting with J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to discuss liquidation analysis and upcoming call.	0.40
10/08/20	JD	Meeting with J. Lowne (Purdue), J. DelConte, H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss draft liquidation analysis and next steps.	0.80
10/08/20	JD	Meeting with J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to discuss next steps re: liquidation analysis.	0.30
10/08/20	JD	Review latest draft liquidation analysis prior to call.	0.70
10/08/20	JD	Call with J. DelConte, K. McCafferty, S. Lemack (all AlixPartners) re: liquidation analysis.	0.50
10/09/20	HSB	Review Purdue financial statements and related documents for preparing open items list for liquidation analysis	0.30
10/12/20	SKL	Continue to update debtor by debtor liquidation costs based on the latest total assets by debtor allocation.	1.50
10/14/20	HSB	Review correspondence from Fidelity re: Purdue pension plan	0.20
10/15/20	SKL	Updated the PBGC section of the liquidation analysis with the latest information provided by Fidelity and updated in	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		the debtor tabs of the liquidation analysis accordingly.	
10/16/20	SKL	Prepare updates to the Chapter 7 Trustee fees of the liquidation analysis and ensured updates were allocated to each debtor entity.	1.60
10/16/20	SKL	Update call with H. Bhattal, S. Lemack (both AlixPartners) to discuss liquidation analysis and related open items	0.40
10/16/20	HSB	Update call with H. Bhattal, S. Lemack (both AlixPartners) to discuss liquidation analysis and related open items	0.40
10/19/20	SKL	Continue to finalize updates to the draft liquidation analysis prior to meeting with J. Carlisle (Purdue)	1.30
10/20/20	SKL	Review and make updates to the inventory section of the liquidation analysis.	0.90
10/20/20	SKL	Call with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) and J. Carlisle (Purdue) re: liquidation analysis.	0.70
10/20/20	SKL	Continue to prepare and finalize updates to the liquidation analysis and circulate meeting invite to D. Fogel (Purdue) accordingly.	1.90
10/20/20	JD	Call with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) and J. Carlisle (Purdue) re: liquidation analysis.	0.70
10/20/20	JD	Review latest draft liquidation analysis prior to call with the company.	1.10
10/20/20	HSB	Call with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) and J. Carlisle (Purdue) re: liquidation analysis.	0.70
10/21/20	JD	Call with D. Fogel (Purdue) re: liquidation analysis.	0.30
10/22/20	JD	Meeting with D. Fogel (Rhodes Tech), W. DiNicola (Rhodes Tech), R. Haberlin (Rhodes Pharma), Jon Carlisle	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		(Purdue), H. Bhattal, J. DelConte, A. DePalma, S. Lemack (all AlixPartners) to review liquidation analysis, discuss open items, and next steps.	
10/22/20	SKL	Meeting with D. Fogel (Rhodes Tech), W. DiNicola (Rhodes Tech), R. Haberlin (Rhodes Pharma), Jon Carlisle (Purdue), H. Bhattal, J. DelConte, A. DePalma, S. Lemack (all AlixPartners) to review liquidation analysis, discuss open items, and next steps.	0.50
10/22/20	HSB	Meeting with D. Fogel (Rhodes Tech), W. DiNicola (Rhodes Tech), R. Haberlin (Rhodes Pharma), Jon Carlisle (Purdue), H. Bhattal, J. DelConte, A. DePalma, S. Lemack (all AlixPartners) to review liquidation analysis, discuss open items, and next steps.	0.50
10/22/20	ADD	Meeting with D. Fogel (Rhodes Tech), W. DiNicola (Rhodes Tech), R. Haberlin (Rhodes Pharma), Jon Carlisle (Purdue), H. Bhattal, J. DelConte, A. DePalma, S. Lemack (all AlixPartners) to review liquidation analysis, discuss open items, and next steps.	0.50
10/23/20	ADD	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to review the liquidation analysis, discuss open items, and set up next steps.	0.60
10/23/20	HSB	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to review the liquidation analysis, discuss open items, and set up next steps.	0.60
10/23/20	HSB	Review terms of DOJ settlement agreement and assessed the impact on treatment of various claims	1.10
10/23/20	SKL	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to review the liquidation	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
10/23/20	JD	analysis, discuss open items, and set up next steps. Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) to review the liquidation analysis, discuss open items, and set up next steps.	0.60
10/23/20	JD	Review liquidation analysis in advance of call with Purdue management.	0.30
10/26/20	SKL	Prepare updates to the liquidation analysis based on latest feedback provided on recovery rates and assumptions.	1.20
10/27/20	SKL	Continue to finalize updates to the latest liquidation analysis and prepare updated listed of open items.	1.80
10/28/20	SKL	Review latest P&L by debtor report provided by B. Sielert (Purdue) and continue updating liquidation analysis accordingly.	1.80
10/30/20	SKL	Meeting with H. Bhattal, S. Lemack (both AlixPartners) to discuss latest and upcoming liquidation analysis updates.	0.80
10/30/20	HSB	Meeting with H. Bhattal, S. Lemack (both AlixPartners) to discuss latest and upcoming liquidation analysis updates.	0.80
Total			48.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	3.00	515.00	1,545.00
Sam K Lemack	29.80	515.00	15,347.00
HS Bhattal	8.90	840.00	7,476.00
Kevin M McCafferty	0.50	950.00	475.00
Jesse DelConte	6.20	950.00	5,890.00
Total Hours & Fees	48.40		30,733.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
10/06/20	ADD	Meeting with A. DePalma and S. Lemack (both AlixPartners) to discuss trade claims filed and begin preparing trade claims summary.	0.30
10/06/20	SKL	Meeting with A. DePalma and S. Lemack (both AlixPartners) to discuss trade claims filed and begin preparing trade claims summary.	0.30
10/07/20	SKL	Meeting with A. DePalma and S. Lemack (all AlixPartners) to discuss trade claims filed and finalize trade claims summary report.	0.60
10/07/20	ADD	Meeting with A. DePalma and S. Lemack (all AlixPartners) to discuss trade claims filed and finalize trade claims summary report.	0.60
10/08/20	ADD	Review filed trade claims and create trade claims reconciliation.	2.50
10/09/20	ADD	Review trade potential duplicate/redundant claims.	1.30
10/09/20	JD	Review and provide comments on the trade claim information summary for management.	0.50
10/09/20	JD	Correspondence with Purdue management re: retiree LTRP payments.	0.30
10/13/20	SKL	Continue update the latest Prime Clerk claims report and update the AlixPartners claims database accordingly.	2.10
10/13/20	SKL	Review and reconcile latest Prime Clerk claims report and prepare updated trade claims summary and detail accordingly.	1.70
10/14/20	ADD	Update trade claims reconciliation spreadsheet in preparation for trade claims meeting.	2.40
10/15/20	ADD	Meeting with J. Lowne (Purdue) to discuss the claims process and latest updates re: trade claims filed.	0.40
10/20/20	ADD	Meeting with J. Lowne (Purdue), S. Lemack, A. DePalma	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		(both AlixPartners) to discuss the claims process and latest updates re: trade claims filed.	
10/20/20	SKL	Meeting with J. Lowne (Purdue), S. Lemack, A. DePalma (both AlixPartners) to discuss the claims process and latest updates re: trade claims filed.	0.40
10/23/20	SKL	Conversation with S. Lemack and J. DelConte (both AlixPartners) re: claims.	0.50
10/23/20	SKL	Prepare updated list of open items re: claims review process, and circulate meeting invite to DPW team accordingly to discuss.	0.50
10/23/20	JD	Conversation with S. Lemack and J. DelConte (both AlixPartners) re: claims.	0.50
10/26/20	JD	Call with A. DePalma, H. Bhattal, S. Lemack and J. DelConte (all AlixPartners), C. Robertson (Davis Polk) re: Purdue Claims discussion	0.80
10/26/20	SKL	Call with A. DePalma, H. Bhattal, S. Lemack and J. DelConte (all AlixPartners), C. Robertson (Davis Polk) re: Purdue Claims discussion	0.80
10/26/20	ADD	Call with A. DePalma, H. Bhattal, S. Lemack and J. DelConte (all AlixPartners), C. Robertson (Davis Polk) re: Purdue Claims discussion	0.80
10/26/20	HSB	Call with A. DePalma, H. Bhattal, S. Lemack and J. DelConte (all AlixPartners), C. Robertson (Davis Polk) re: Purdue Claims discussion	0.80
10/27/20	ADD	Call with A. DePalma, S. Lemack and J. DelConte (all AlixPartners) re: Purdue claims accounting discussion	0.30
10/27/20	SKL	Call with A. DePalma, S. Lemack and J. DelConte (all AlixPartners) re: Purdue claims accounting discussion	0.30
10/27/20	SKL	Review latest claims report provided by Prime Clerk and update claims database prior to DPW claims meeting.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
10/27/20	SKL	Review latest vendor inquiry provided by H. Benson (Purdue) and prepare updated AP and claims breakdown.	0.70
10/27/20	JD	Call with A. DePalma, S. Lemack and J. DelConte (all AlixPartners) re: Purdue claims accounting discussion	0.30
Total			21.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	9.00	515.00	4,635.00
Sam K Lemack	9.60	515.00	4,944.00
HS Bhattal	0.80	840.00	672.00
Jesse DelConte	2.40	950.00	2,280.00
Total Hours & Fees	21.80		12,531.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
10/01/20	KG	Export and prepare documents for delivery as requested by A. DePalma.	1.90
10/01/20	ADD	Compile and review Rhodes Technologies contracts in preparation for closing.	2.40
10/01/20	ADD	Review agreements shared with Rhodes Tech bidders and identify additional agreements to be shared via the data room.	1.90
10/02/20	ADD	Call with K. Kolar (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst tech transfer planning for Rhodes Pharma.	1.20
10/06/20	ADD	Update Rhodes Tech master contracts database.	1.80
10/12/20	ADD	Update Rhodes Tech contract spreadsheet for client review.	1.20
10/14/20	ADD	Compile Rhodes Tech contracts and upload to the data room for Skadden's review.	3.10
10/14/20	ADD	Review Rhodes tech contract list and identify outstanding agreements.	1.70
10/14/20	KG	Overlay new metadata file into Relativity.	0.60
10/15/20	ADD	Compile Rhodes Tech contracts and upload to the data room for buyer's review.	2.40
10/18/20	ADD	Compile Rhodes Tech contracts and upload to the data room for buyer's review.	2.80
10/19/20	ADD	Review outstanding diligence requests and draft correspondence requested responsive materials.	0.50
10/22/20	ADD	Call with A. DePalma, K. McCafferty and others (all AlixPartners) re: Smartsheet IMO Assistance	0.70
10/23/20	ADD	Prepare for AlixPartners engagement team Purdue AP Team Update Call.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
10/23/20	ADD	Reconcile Rhodes tech Assigned contract list with Rhodes tech master contract list to identify discrepancies.	2.30
10/23/20	ADD	Reconcile Rhodes tech executed contract list with Rhodes tech master contract list to identify discrepancies.	2.70
10/26/20	ADD	Meeting with S. Engel, J. Narliss (Purdue), P. Brinkerhoff, M. Gupta, N. Feldman, A. Raina (all Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: IT workstream update.	0.50
10/26/20	ADD	Compare assigned contract schedule to Rhodes Tech Master Contract List to identify missing agreements.	2.70
10/26/20	ADD	Continue to compare excluded contract schedule to Rhodes Tech Master Contract List to identify missing agreements.	2.40
10/27/20	ADD	Review Rhodes Tech agreements designated as excluded, assigned, and executory to compare classifications.	1.70
10/28/20	ADD	Update Rhodes tech contract classifications identifying lab and IT contracts in the master contract list.	1.40
10/28/20	ADD	Compile and upload Rhodes Tech agreements to the data room for legal review.	2.30
10/29/20	ADD	Update Rhodes Tech master contract list with feedback from legal counsel.	2.20
Total			40.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	38.30	515.00	19,724.50
Kristina Galbraith	2.50	645.00	1,612.50
Total Hours & Fees	40.80		21,337.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
10/01/20	KAS	Review draft 12th monthly fee statement.	0.40
10/07/20	JD	Review and provide comments on final August fee application and send off for sign off.	0.70
10/08/20	MSM	Prepare professional fees for September 2020 fee application.	2.50
10/09/20	MSM	Prepare professional fees for September 2020 fee application.	1.20
10/11/20	MSM	Prepare professional fees for September 2020 fee application.	2.70
10/11/20	MSM	Continue to prepare professional fees for September 2020 fee application.	3.30
10/11/20	MSM	Prepare professional fees for September 2020 fee application.	2.00
10/13/20	TB	Update twelfth monthly fee statement and exhibit.	0.20
10/19/20	KAS	Review draft supplemental declaration.	0.30
10/20/20	MSM	Prepare professional fees for October 2020 fee statement.	3.00
10/21/20	MSM	Prepare professional fees for October 2020 fee statement.	2.70
10/22/20	KAS	Review updated supplemental declaration.	0.20
10/23/20	KAS	Respond to D. Consla (DP) comment to supplemental disclosure.	0.60
10/24/20	MSM	Prepare professional fees for October 2020 fee statement.	3.70
10/27/20	MSM	Prepare professional fees for October 2020 fee statement.	1.60
10/27/20	JD	Begin review of September fee statement.	2.20
10/27/20	JD	Finalize review of September fee statement.	2.50
10/28/20	JD	Final review of fee statement.	0.50
10/28/20	KAS	Review draft thirteenth monthly statement.	0.60
10/28/20	TB	Prepare thirteenth monthly fee statement and exhibit for	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		September 2020.	
10/30/20	TB	Email to M. Pera, D. Consla, C. Robertson (all David Polk) attaching the eleventh monthly fee statement September 2020 for filing with the court.	0.20
Total			32.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Melanie McCabe	22.70	415.00	9,420.50
Tammy Brewer	1.60	450.00	720.00
Kaitlyn A Sundt	2.10	510.00	1,071.00
Jesse DelConte	5.90	950.00	5,605.00
Total Hours & Fees	32.30		16,816.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
10/28/20	NAS	Attend 10/28 Telephonic Court Hearing (partial).	1.00
10/28/20	JD	Participate in Purdue court hearing telephonically.	3.10
10/28/20	HSB	Attended Bankruptcy Court Hearing Re: Keip & DOJ settlement.	2.10
Total			6.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	1.00	515.00	515.00
HS Bhattal	2.10	840.00	1,764.00
Jesse DelConte	3.10	950.00	2,945.00
Total Hours & Fees	6.20		5,224.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/01/20	RC	Review and comment on cash transfer of value report support documentation gathered in response to the UCC's requests.	0.80
10/02/20	RC	Review support documentation related non-tax distributions.	1.10
10/02/20	RC	Additional review of support documentation related to the cash transfers of value report.	0.80
10/05/20	RC	Review and comment on documents gathered in response to requests from the UCC.	1.40
10/05/20	RC	Review documents related to requests from the UCC's advisors.	0.60
10/05/20	RC	Review mediators status report.	0.30
10/06/20	RC	Call with S. Canniff, R. Collura (both AlixPartners) to discuss support documentation related to the UCC's requests.	0.60
10/06/20	SJC	Call with S. Canniff, R. Collura (both AlixPartners) to discuss support documentation related to the UCC's requests.	0.60
10/07/20	SJC	Call with A. DePalma and S. Canniff (both AlixPartners) to discuss support documentation related to the UCC's requests.	0.40
10/07/20	SJC	Call with A. DePalma and S. Canniff (both AlixPartners) re: 2008 and 2009 UCC diligence request working session.	0.50
10/07/20	SJC	Review and research 2008 and 2009 UCC diligence request.	3.00
10/07/20	SJC	Continue review and research 2008 and 2009 UCC diligence request.	2.70
10/07/20	RC	Review UCC's request for examination of certain	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		executives and Norton Rose.	
10/07/20	RC	Review support documentation gathered in response to requests from the UCC.	0.70
10/07/20	ADD	Call with A. DePalma and S. Canniff (both AlixPartners) to discuss support documentation related to the UCC's requests.	0.40
10/07/20	ADD	Call with A. DePalma and S. Canniff (both AlixPartners) re: 2008 and 2009 UCC diligence request working session.	0.50
10/08/20	RC	Review support documentation and respond to questions from the UCC re: distributions.	1.20
10/14/20	RC	Review additional information gathered in response to UCC's requests for tax distribution support	0.70
10/16/20	RC	Review additional documents gathered in response to requests from the UCC.	1.40
10/20/20	RC	Review support documentation gathered in response to requests from the UCC.	1.30
10/21/20	RC	Review additional documentation gathered in response to UCC's requests for distribution related information.	0.80
10/22/20	RC	Gather information related to Ex-US distributions in response to requests from Davis Polk.	1.50
10/22/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) to discuss requests for documentation related to Ex-US distributions.	0.60
10/22/20	RC	Review additional documentation gathered in response to the UCC's requests.	0.80
10/22/20	JD	Call with A. DePalma, S. Lemack, and J. DelConte (AlixPartners), T. Melvin and J. Turner (PJT), and Davis Polk team re: Deposition prep.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/22/20	SKL	Call with A. DePalma, S. Lemack, and J. DelConte (AlixPartners), T. Melvin and J. Turner (PJT), and Davis Polk team re: Deposition prep.	0.50
10/22/20	ADD	Compile requested distribution data and supporting documentation at the request of Davis Polk.	2.80
10/22/20	ADD	Compile and upload Rhodes Tech agreements for buyer review.	1.80
10/22/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) to discuss requests for documentation related to Ex-US distributions.	0.60
10/22/20	ADD	Call with A. DePalma, S. Lemack, and J. DelConte (AlixPartners), T. Melvin and J. Turner (PJT), and Davis Polk team re: Deposition prep.	0.50
10/23/20	RC	Gather support documentation requested by the UCC related to non-tax distributions	1.20
10/29/20	RC	Review support documentation gathered in response to UCC's requests	0.70
10/29/20	RC	Review tax documentation gathered in response to the UCC's request	0.60
10/30/20	RC	Review of non-tax distribution support documentation.	1.00
10/30/20	RC	Review tax amount reconciliations.	0.60
10/30/20	RC	Review additional documentation gathered in response to the UCC's requests for distribution information.	0.80
Total			34.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	6.60	515.00	3,399.00
Sam K Lemack	0.50	515.00	257.50
Sam J Canniff	7.20	645.00	4,644.00
Jesse DelConte	0.50	950.00	475.00
Richard Collura	19.80	1,090.00	21,582.00
Total Hours & Fees	34.60		30,357.50

Exhibit B

AlixPartners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
09/22/20	Conference Calls - - VENDOR: Vodafone US Inc	3.13
09/25/20	Conference Calls - - VENDOR: Vodafone US Inc	1.76
	Total Disbursements	4.89

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2129494-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Other	4.89
Total Disbursements	4.89